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Abstract 
The estrogen receptor(ER) is a master transcriptional regulator in the breast where it 
plays key roles in the development and maintenance of normal breast epithelium but is 
also critical to the growth of luminal breast cancers. ER is also a well-defined molecular 
therapeutic target and anti-estrogens, such as tamoxifen, are used clinically to inhibit the 
mitogenic activity of ER and delay disease progression. However, despite the initial 
benefits to tamoxifen therapy, nearly one third of luminal breast cancer tumors 
eventually become resistant, limiting the therapeutic utility the drug. Mechanisms of 
resistance can be attributed to circumvention of ER and reliance on alternative growth 
pathways, or through upregulation of pathways that converge with ER to allow 
reactivation. Understanding the molecular determinants of resistance is a critical 
endeavor that demands attention in order to shape new drug developments and extend 
the therapeutic efficacy of anti-estrogens. 
 A major challenge in elucidating mechanisms of resistance is in understanding the 
complexities of the ER signaling program in respect to receptor occupancy and the 
coordinated relationship with chromatin architecture and collaborating transcription 
factors. This work therefore integrates the relationship between accessible chromatin, as 
measured by DNase-Seq, with ER occupancy and ER-mediated transcription in an in 
vivo derived tamoxifen resistant cell line (TamR) and a comparator group of two closely 
related tamoxifen sensitive cell lines. Cumulatively, these data demonstrate an enhanced 
 v 
role for FOXA1 in tamoxifen resistance. Specifically, FOXA1 occupancy is greatly 
enriched at differential DNase hypersensitive loci in TamR cells, and expression of 
nearby genes are transcriptionally upregulated in a FOXA1-dependent manner. 
Furthermore, siRNA directed against FOXA1 can rescue the expression of these target 
genes to MCF7 levels. The TamR cells also have increased ER occupancy at FOXA1 
overlapping sites, where ER is engaged to chromatin in a ligand-independent manner 
and results in enhanced activation of nearby target genes that can be repressed with the 
pure anti-estrogen, ICI. The increased role of FOXA1 is not due to an increase in total 
protein levels however and instead is manifested through increased activity that may 
depend on protein modifications.  
Other clinical associations of resistance have been elucidated for which there is little 
to no mechanistic evidence currently available. The expression of HOXB13 is associated 
with tamoxifen therapy failure from differential microarray expression profiling of 
patients who relapsed compared to those that remained disease-free at the five year 
follow-up. The outcome of our studies elucidates the activity of HOXB13 to 
downregulate the expression of GATA3 which subsequently leads to loss of ER function 
and parallel activation of inflammatory pathways. Forced overexpression of GATA3 in 
this background restores ER expression, partially restores ER target gene expression and 
suppresses the expression of the HOXB13-induced inflammatory genes.  
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The present study also makes use of publicly available clinical datasets to 
generate an integrative database of 4885 patients from 25 independent studies. 
Furthermore, analytical methods and functions were also developed to allow efficient 
use and application of the data. Access to the breast cancer meta-set and functions are 
made available to end users via a web interface, GeneAnalytics. Together, the breast 
cancer meta-set and associated access through the GeneAnalytics web sites provides 
novel opportunities for researchers to integrate functional studies with tumor derived 
expression data to further our understanding of cancer related processes. 
Collectively, our findings demonstrate that the ER signaling program is modified 
as tumors progress to resistance by an increased role of FOXA1 to facilitate ER binding 
and reprogramming, and by HOXB13 to suppress the actions of ER and promote 
inflammatory pathways.  These mechanisms highlight distinct methods of resistance 
and provide rational for new therapeutic approaches to extend the utility of the anti-
estrogens currently in use.  
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1 Introduction 
1.1 Breast Cancer  
1.1.1 General overview 
Breast cancer is a complex, highly prevalent disease that continues to be one of 
the leading causes of death among women.  The American Cancer Society estimates that 
in 2014,  232,670 new cases of breast cancer will be diagnosed and approximately 40,000 
women will die as a result of breast cancer in the USA (Siegel et al., 2014). Breast cancer 
is second only to lung cancer for cancer-related deaths among women but has a higher 
incidence rate overall.  The current lifetime probability of occurrence is 1 in 8 for females 
and current incidence rates are holding steady. Even though incidence rates are less than 
decades past, in part due to better detection and treatment, breast cancer remains a 
significant health burden worldwide and demands further scientific research.  
There are number of risk factors associated with breast cancer including sex, age, 
hormones, BRCA1/2 mutations, and breast density. Upon diagnosis the treatment 
strategy is largely dictated by histopathological features, tumor grade, proliferative 
capacity, metastatic events and tumor subtype. Depending on tumor staging, the patient 
will undergo a series of treatment modalities including surgical resection, radiation 
therapy, cytotoxic agents, endocrine disruption and targeted therapies. Treatment 
timing is also critical. Patients may be given therapeutics, cytotoxics, or radiation prior 
to surgery (neo-adjuvant) with the intent of improving surgical success or delaying 
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progression. Surgical approaches vary based on risk assessment and are primarily aimed 
at reducing tumor burden and removing affected areas of the breast and lymphatic 
system to improve overall survival. Following primary surgical treatment, patients 
remain at risk for recurrent events; whether they occur locally, in the contralateral breast 
or as distant metastases and compel the need for long term therapeutic intervention. The 
risk of recurrence is greatest in the first five years with the peak as early as two years but 
varies widely depending on the tumor subtype. 
1.1.2 Complex heterogeneity 
 Breast cancer is inherently heterogeneous with several distinct biological 
subtypes that vary in prognostic and therapeutic considerations. Clinicians have long 
appreciated that breast cancer cannot be treated as a single disease and routinely 
segregate tumors into manageable phenotypic classes using IHC directed against known 
markers in breast cancer including ERα, PR, HER2 and a proliferation marker such as 
Ki67.   
Thanks to the explosion in genomic technologies we now have a better 
understanding of the molecular determinants that influence breast cancer heterogeneity 
beyond these few markers. In a ground breaking study, Perou and colleagues performed 
unsupervised clustering techniques on microarray data from patient samples and 
observed that the samples clustered into biologically relevant subgroups.  They defined 
the subtypes as Luminal A, Luminal B, Basal-like, HER2-enriched, and Normal-like 
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reflecting their histological counterparts (Perou et al., 2000; Sørlie et al., 2001). They 
further postulated that the difference in expression profiles (molecular portraits) 
underlies the heterogeneity of breast tumors and diverse response to treatments and 
could be distilled down into key features, known as the PAM50 gene-set(Parker et al., 
2009), to identify molecular phenotypes. Furthermore, they also showed that there were 
significant differences in recurrence rates between the clusters; with basal and HER2 
subtypes indicating a worst prognosis and the two Luminal subtypes exhibiting more 
favorable outcomes as seen in Figure 1-1. Subsequent studies have confirmed distinct 
roles for the intrinsic subtypes on incidence, survival and response to treatments 
(Cheang et al., 2009; Millikan et al., 2008; Nielsen et al., 2010; Prat et al., 2010).   
 
Figure 1-1: Intrinsic subtypes stratify prognosis. 
Outcome probability of relapse-free survival in a cohort of 3374 patients as discussed in  
Chapter 4. Intrinsic subtypes were determined using a 50 gene-set classifier (PAM50) and 
subtypes were assigned using a nearest-centroid approach (Parker et al., 2009).  
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1.2 Estrogen Receptor signaling program 
1.2.1 Discovery and importance in breast cancer 
George Beatson, a surgeon in Scotland, was the first to publish on the association 
of hormones produced in the ovaries to the proliferative actions it had on the breast in 
1896 (Beatson, 1897). Taking cues from farmers that removed the ovaries of lactating 
cows to have them produce milk indefinitely, he performed experiments on rabbits to 
validate the dependency(Beatson, 1899). He later detailed three case studies of 
advanced, inoperable breast cancer patients that entered remission following 
oophorectomy (surgical removal of the ovaries)(Beatson, 1896). Based on these 
translational results, Stanley Boyd and others initiated large clinical tests targeting the 
ovaries for surgical removal and observed that roughly one-third of patients benefited 
from ovarian ablation (Boyd, 1902). It’s important to note that these studies were 
performed without any knowledge of the hormones involved or their mechanistic 
actions.  
In 1923, Allen and Doisy identified the responsible estrogenic steroid hormone 
and Doisy later crystallized the first steroid hormone, estrone, in 1929(Allen and Doisy, 
1923).  This discovery prompted research to understand how hormones signal and 
achieve tissue specificity. Fueled by the possibility that hormone action could be 
attributed to specific binding proteins--contrary to prevailing theory--Elwood Jensen 
administered radiolabeled estradiol to rats and found that it was predominately 
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sequestered to the female reproductive tract (Glascock and Hoekstra, 1959; Jensen et al., 
1966). This finding prompted him to suggest that an “estrogen receptor” existed and 
later identified the cell fractions containing the macromolecular complex (Jensen and 
DeSombre, 1973). Since it had been known that only one-third of patients respond to 
ovarian ablation, Jensen predicted that the estrogen receptor levels was the limiting 
factor and hence could determine outcome. He devised a clinical test to assess ER levels 
and found that patients with high amounts of the receptor responded positively while 
those with low amounts did not. This is one the first examples of the use of a predictive 
biomarker in the cancer setting. Subsequent use of antibodies by Greene and Jensen 
allowed for greater sensitivity and enabled quick quantification for more routine use 
(Greene et al., 1980). The ability to stratify tumors that are more likely to respond to 
endocrine therapies and rapid method of testing greatly benefited the clinic and became 
part of the standard of care by the 1980’s. This paradigm of testing laid the groundwork 
for tumor staging and the definition of the clinico-pathological subtypes that have 
evolved into the molecular subtypes in use today.  
1.2.2 Mechanism of ER function 
Estrogenic ligands and their cognate receptors are essential for a myriad of 
normal physiological processes and play pivotal roles in numerous diseases states(Burns 
and Korach, 2012).  Estrogens are predominately produced in the ovaries and, like other 
steroidal hormones, are synthesized from precursors derived from a common 
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cholesterol backbone. The culminating step in the biosynthesis of estrogens requires the 
CYP19 aromatase, a P450 enzyme that converts androstenedione into estrone or 
testosterone into estradiol. Estrone can also be reduced to estradiol by 17β-
hydroxysteroid dehydrogenase. Estradiol is the most abundant circulating estrogen 
during pre-menopausal years and its levels are coupled to the menstrual cycle where it 
increases sharply near the end of the follicular phase just prior to ovulation. Owing to its 
physicochemical properties as a steroid, estrogens are lipophilic and can freely diffuse 
into cells where it interacts with the estrogen receptor.  
The biological activities of estrogens in cells are mediated by the estrogen 
receptor, a ligand-dependent transcription factor and a member of the nuclear receptor 
superfamily. In the absence of ligand, ER resides in the cytosol in an inactive monomeric 
form bound to heat shock proteins. Upon binding ligand, the receptor undergoes a 
conformation change,  dissociates from the heat shock complex, dimerizes and 
translocates to the nucleus where it interacts directly with DNA at a specific motif 
commonly known as the estrogen response element (ERE).  The canonical ERE is 
defined as an inverted repeat of DNA half sites also known as a palindrome and is based 
on the Xenopus laevis vitellogenin A2 promoter: 5’-GGTCAnnnTGACC-3’(Gruber et al., 
2004). Upon binding to DNA, ER recruits a multitude of coregulatory factors including 
transcriptional coactivators, histone acetyltransferases (HATs), histone 
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methyltransferases (HMTs), and other chromatin remodelers to promote a permissive 
chromatin environment for transcription.  
While it was initially thought that the receptor was limited to an active or 
inactive conformation, it is now understood that the structure and response is not 
binary. Each ligand confers a unique conformation and allows for a spectrum of 
activities (Norris et al., 1999). The biological response therefore hinges upon the ligand-
induced conformational change and dictates key facets of regulation including cofactor 
binding profiles, DNA binding preferences and receptor turnover(Rosenfeld and Glass, 
2001). 
ER is a member of the Class I nuclear receptors which function as homodimers 
on DNA and include the glucocorticoid receptor, androgen receptor, mineralocorticoid 
receptor and progesterone receptor(Bain et al., 2007; Beato and Klug, 2000; Weatherman 
et al., 1999). The transcriptional activity of the estrogen receptor is mediated by two key 
functional domains termed AF-1 and AF-2 which contain key docking surfaces for 
coregulators and serves also as sites for protein modifications (Figure 1-2)(Tremblay et 
al., 1999; Webb et al., 1998). Like other nuclear receptors, the estrogen receptor shares the 
typical patterning of structural domains A-F. The N-terminal A/B domain contains 
activating function 1 (AF-1) and its activity does not require ligand binding per se, but is 
manifest upon the delivery of the receptor to DNA. There are several phosphorylation 
sites (S104, S106, S118, and S167) with AF-1 that are the targets of growth factor 
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regulated kinases and impact the functionality of this transcriptional domain.  The C 
domain represents the DNA-binding domain (DBD) with its two zinc fingers and plays 
a minor role in receptor dimerization. The D-domain or hinge region contain a nuclear 
localization sequence and is necessary for complete activation and synergy between the 
AF-1 and AF-2 domains (Zwart et al., 2010). The E domain contains the ligand-binding 
domain (LBD) and AF-2 the activity of which is influenced by ligand-dependent changes 
of the receptor. Ligand binding induces a structure which allows helix 3, 4, 5, and 12 to 
form a shallow hydrophobic groove that exposes a surface that recognizes a commonly 
conserved LXXLL motif on coactivators. The E domain also contains a strong 
dimerization sequence. Lastly, the carboxy-terminal F domain is reported to be 
necessary in mediating the effects of antagonists (Montano et al., 1995) and is important 
for receptor turnover (Wittmann et al., 2007). 
Two molecular forms of the estrogen receptor have been identified in humans, 
ERα and ERβ, which are encoded by separate genes ESR1 and ESR2 
respectively(Dupont et al., 2000; Hewitt and Korach, 2003; Ruff et al., 2000). The 
receptors are transcribed from different chromosomes and while both receptors are 
expressed in most cells, the expression of one or both subtypes has been observed in 
some cells. The amino acid structure of ERα and ERβ are highly homologous yet they 
mediate distinct biological activities (Figure 1-2). ERβ is more highly expressed in the 
prostate, ovaries, lungs, and nervous systems while ERα is predominately expressed in 
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the breast, uterus, pituitary gland, liver, kidneys, and adrenal gland (Zilli et al., 2009). 
Both forms are expressed in the breast and their interplay and ability to oppose one 
another has been subject to an evolving debate on clinical implications and therapeutic 
strategies (Grober et al., 2011; Hall and McDonnell, 1999; Katzenellenbogen and 
Katzenellenbogen, 2000). ERα is a more robust transactivator and experimentally ERβ 
has been shown to suppress the activities of ERα (Hall and McDonnell, 1999). The 
absolute and relative ratios are therefore important in determining the overall response. 
The differences in activity can be attributed to distinct sequence compositions of the 
receptors themselves. ERα is composed of 595 amino acids and ERβ has 530.  The 
relative differences and similarities are further exemplified in the degree of homology 
across the different domains (Figure 1-2). In particular, it is notable that the DBD is 97% 
conserved while the A/B domain containing AF-1 is only 18% conserved.  
 
 
Figure 1-2: ER structure and homology. 
A schematic representation of the protein structural domains and key features of the ER receptors. 
Listed above are the nuclear receptor derived domains A-F. The numbers inside the box refer to 
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the number of amino acids and total amino acids to the right. Amino acid percent homology is 
listed below.  
 
Genome wide profiling of ER binding sites has confirmed that the canonical ERE 
is the most prominent DNA motif present  within the regulatory regions of these target 
genes, but also that the homo-dimerized receptor binding preferences are somewhat 
flexible and allow for some variations beyond the canonical sequence (Hurtado et al., 
2011a; Kong et al., 2011b; Ross-Innes et al., 2012a; Welboren et al., 2009). Adding another 
layer of complexity is the fact that many ER binding sites contain only a partial ERE and 
other regions do not bear any resemblance to an ERE. In addition to the classical mode 
of ER action, ER can also interact with DNA in an indirect manner via tethering to other 
transcription factors including binding to FOS and JUN at activator protein 1 (AP-1) 
elements, to specificity protein 1 (SP1), or to nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) (Figure 1-3). Presumably tethered complexes and other 
factors that stabilize ER at imperfect EREs account for the binding anomalies observed in 
global binding studies.  
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Figure 1-3: ER signaling mechanisms. 
Illustration of the ER signaling pathway. Key phosphorylation sites are pictured and also three 
distinct methods that allow ER to associate with chromatin. Classical: direct binding of EREs. 
Tethering: protein-protein interaction with general transcription factors. Collaborating: 
Stabilization of binding through adjacent factors.  
 
A recent study leveraged the peculiarity of ER binding sites at imperfect EREs to 
elucidate their relationship across different cell types (Gertz et al., 2013). They compared 
the ER cistrome of T-47D cells (breast) and ECC-1 (endometrial) cells for the sequence 
determinants of binding relative to chromatin accessibility as determined by DNase-Seq. 
In agreement with the observation of cell-specific ER activities, ER binding sites were 
also diverse and subsets of cell-specific and shared (~10%) sites were identified. Roughly 
one-third of all sites had no discernible ERE and these were three times more likely to be 
found within genes that are expressed in a cell selective manner. Moreover, shared sites 
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were enriched in high affinity EREs while cell-specific sites contained lower affinity 
EREs but also were strongly associated with other transcription factor motifs that were 
expressed in a cell-specific manner.  
1.2.3 Coregulators 
Transcriptional activation by ER involves a coordinated interplay between the 
receptor, ligand, chromatin, and coregulators for robust activation of target genes. Upon 
associating with chromatin, coactivators are recruited to ER and impart transcriptional 
regulation by remodeling local chromatin and permitting RNA polymerase activity. The 
first glimpse of coactivator function was revealed with the observation that transcription 
factors can interfere with one another through a phenomenon known as squelching, an 
event attributed to a limited supply of a factor absolutely necessary for activation and 
results in reduced activation of both receptors. Later, a yeast two-hybrid screen 
recovered SRC-1 and found it to bind to both PR and ER and that over expression of 
SRC-1 could mitigate the squelching effects known to occur between the two receptors 
(Oñate et al., 1995). 
 Hundreds of coactivators have been identified and the majority contain a 
signature leucine-rich motif (LXXLL), also called the NR box, which is both necessary 
and sufficient for binding to ER (Heery et al., 1997). Crystallization studies of the LBD of 
ER and a fragment of PPARγ have elucidated that coactivators bind to a hydrophobic 
cleft of the receptor comprising helices 3, 4, 5 and 12 through a specific interaction with 
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the LXXLL motif (Nolte et al., 1998).  Flanking amino acids of the motif were also found 
to be important in receptor selectivity and activity (Chang et al., 1999). 
 The ligand-induced conformation of ER dictates coregulator binding profiles. 
Crystal structures of ER have elucidated that helix 12 is highly mobile in response to the 
nature of the bound ligand and truncation of helix 12 at 535 abolishes coregulator 
binding. Antagonists bound by the receptor results in a unique conformation of the 
receptor and repositions helix 12 effectively blocking the LXXL interaction motif thereby 
rendering ER activity null (Shiau et al., 1998). Antagonists, including tamoxifen, and 
their role on coregulator recruitment will be discussed in section 1.3. 
The fundamental unit of chromatin is the nucleosome and consists of DNA 
wrapped around a histone octamer in a 147bp stretch. Nucleosomes play an important 
role in inhibiting gene expression by blocking access of regulatory proteins and RNA 
polymerase to DNA. Consequently, chromatin structure must be reorganized by 
nucleosome loss, rearrangement or displacement during transcriptional activation or 
preset to allow activation. The N-terminal tails of core histones are subject to 
modifications (acetylation, methylation, phosphorylation and ubiquitination) and play a 
fundamental role in structural organization of chromatin and in recruiting effector 
molecules for transcriptional initiation and elongation(Hebbes et al., 1988; Lee et al., 
1993).  Coactivators that possess enzymatic functions, such as the P160 family which 
contain domains for HAT activity, have an active role in this process, while others act as 
 14 
scaffolds enabling the assembly of secondary protein complexes(Halachmi et al., 1994; 
Oñate et al., 1995). Multi-protein complexes are common and contain HATs (p300, CBP, 
p/CAF, and the P160 family), HMTs (PRMT1 and CARM1) and ATPases (SWI/SNF) that 
together destabilize nucleosomes and facilitate association with mediator complexes to 
promote PolII initiation.  
In addition to coactivators, corepressors are equally important in negatively 
regulating ER activity. ER can actively repress genes in a ligand-dependent manner by 
recruitment of corepressors to silence gene expression. Diametric in function, 
corepressors interact with ER to mitigate transcriptional activation by facilitating 
chromatin condensation.  Interaction of the corepressors with ER is mediated through 
the CoRNR box of ER (Shang et al., 2000). Corepressors include NCoR, SMRT, NRIP1, 
SAFB1, REA, and HDACs. These rely upon secondary factors that allow them to exert 
repressive effects. As an example, both NCoR and SMRT associate with HDAC3 in order 
to achieve transcriptional silencing.  
1.2.4 Chromatin dynamics and collaborating factors 
The simplified model of ER signaling entails ligand bound receptor associating 
with chromatin where it recruits coregulators and activates target gene expression. 
However, genome wide chip studies have revealed that a transcription factor generally 
only occupies a small fraction of the potential number of high affinity binding sites 
available within the genome(Johnson et al., 2007). Simply stated, chromatin features 
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beyond DNA sequence are important determinants of whether a factor can indeed bind 
to DNA. The simplified model can therefore be expounded upon with the idea that ER 
predominately binds to regions of open chromatin and that the chromatin landscape 
therefore governs binding capacity. As each tissue has distinct profiles of open 
chromatin (Song et al., 2011a), distinct ER binding profiles are also observed and this 
results in unique gene expression patterns. This raises the question of how binding sites 
become competent and what factors are necessary for an intact ER signaling program. 
Our understanding of the fundamental aspects of ER activity has evolved with 
the burgeoning information obtained from genome-wide studies. The use of chromatin 
immunoprecipitation coupled with genome wide microarrays (ChIP-chip) or next 
generation sequencing (ChIP-Seq and ChIP-exo) (Johnson et al., 2007; Rhee and Pugh, 
2011) have allowed global identification of ER binding sites in an unbiased manner 
(Carroll et al., 2005; Hurtado et al., 2011a; Joseph et al., 2010; Kong et al., 2011b; Ross-
Innes et al., 2012a; Welboren et al., 2009).  The estrogen receptor has been subject to a 
large number of genome profiling studies and these have revealed that the majority of 
ER binding events occur in cis-regulatory distal enhancer regions as opposed to 
proximal promoter regions. Motif enrichment analyses of ER binding sites have also 
revealed that other transcription factor motifs are commonly associated with ER, namely 
the pioneer factor FOXA1 (Carroll et al., 2005; Ross-Innes et al., 2012b). 
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 Pioneer factors are defined by their ability to associate to DNA elements within 
condensed chromatin and permit other transcription factors to bind (Figure 1-4) (Cirillo 
et al., 2002; Lupien et al., 2008). 
 
Figure 1-4: Pioneer factors facilitate chromatin opening. 
Pioneer factors can directly interact with nucleosomes to allow access for other general 
transcription factors such as ER.  
 
 
 Pioneer factors are required for initiation of transcription and also play a role in 
maintaining competency of an enhancer by active presence. FOXA1 has been profiled by 
ChIP-Seq in MCF-7 cells and nearly half of all ER binding sites are coincident with 
FOXA1 sites (Hurtado et al., 2011b). Further substantiating ER’s dependency on FOXA1, 
siRNA directed against FOXA1 results in loss of ER binding at these loci and 
concomitant decrease in target gene expression (Eeckhoute et al., 2006; Laganière et al., 
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2005). Conversely, loss of ER has little to no impact on FOXA1 binding as binding is 
independent of ER actions (Hurtado et al., 2011b). In another study, forced 
overexpression of ER, GATA3, and FOXA1 could recapitulate a complete ER signaling 
program in an ER negative cell line while ER expression alone could not (Kong et al., 
2011b).  
 FOXA1 is a member of the forkhead family of transcription factors that were 
originally defined for their developmental role in the liver (Nagy et al., 1994). The 
pioneering capacity of FOXA1 is embodied in the forkhead domain, which is a variant of 
the helix-turn-helix structure and is composed of two large loops that resemble a winged 
helix. The structure of the winged helix is notable because it is highly similar to linker 
histone structure and also possesses DNA binding capacity allowing it to both bind 
nucleosome core particles and DNA simultaneously (Chaya et al., 2001).  FOXA1 
therefore facilitates ER binding by associating to condensed chromatin, displacing H1 
linker histones and destabilizing the nucleosome allowing for other factors to engage 
DNA. Its ability to open condensed chromatin is ATP-independent and there is evidence 
that it binds nucleosomal DNA more strongly than to naked DNA (Cirillo and Zaret, 
1999). FOXA1 also maintains competency of the binding site by inhibiting nucleosome 
condensation and is retained on DNA through mitosis acting as a bookmark for 
subsequent nucleosome positioning.  Lastly, it is important to note that FOXA1, like 
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other transcription factors, does not bind to every available motif in the genome, 
indicating that additional levels of specificity exist.  
As genomic technologies have advanced, it is now clear that chromatin dynamics 
are closely associated with and contingent upon DNA methylation, nucleosome 
positioning, and epigenetic features (Thurman et al., 2012).  Despite its role a pioneer 
factor, FOXA1 binding activity can be altered by certain chromatin modifications. Due to 
binding constraints in its forkhead domain, FOXA1 associates poorly with methylated 
DNA. Additional studies suggest that the binding of FOXA1 to chromatin is governed 
by epigenetic modifications on histone H3, specifically on the mono- and di-methylation 
of histone H3 at lysine 4 (H3K4me1 and H3K4me2). Experimental evidence has 
indicated that the demethylation of histone sites by LSD1 inhibits FOXA1 binding 
(Eeckhoute et al., 2009; Lupien et al., 2008; Sérandour et al., 2011), suggesting that H3K4 
methylation is necessary and intricately linked to FOXA1 activity. 
While FOXA1 is the prototypical pioneer factor and essential to an intact ER 
signaling program, there is considerable interest in identifying other factors that harbor 
the ability to modify chromatin and reprogram ER binding preferences. This may be 
especially important in disease states where ER elicits a gain of function beyond normal 
physiological roles, an effect that may be attributed to ER reprogramming by pioneer 
factors. To date, there have been a handful of factors identified through enrichment 
analysis procedures around ER binding sites and include GATA3, AP-2, TLE1, and PBX1 
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(Holmes et al., 2012; Joseph et al., 2010; Kong et al., 2011b; Magnani et al., 2011).   
Intriguingly, expression of many of these factors highly correlates with ER and are part 
of the minimal definition of a luminal cell type (Perou et al., 2000), and further 
exemplifies their roles in a broad regulatory network to support ER function. There is 
ample evidence that FOXA1, TLE and GATA factors shapes enhancers by binding 
directly to condensed chromatin but as yet there is minimal evidence to support such 
roles for PBX1 or AP-2 factors. Nonetheless, AP-2 was found to bind almost 60% of the 
ER cistrome and siRNA directed against AP-2 was able to abolish ER occupancy at a 
subset of sites (Tan et al., 2011b). AP-2 and FOXA1 were also found to work 
cooperatively, both being necessary for complete activation. Altogether there is 
considerable overlap (Figure 1-5) in binding among the recognized pioneer factors yet 
specific binding profiles do exist for each. Further studies are necessary to understand 
the biological outcomes as they relate to the composite binding profiles and what 
specific subsets contribute to breast cancer progression.  
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Figure 1-5: Overlap of pioneer factor binding. 
Composite profiles of pioneer factor binding sites from ChIP-Seq studies. Figure adapted from 
Jozwik, 2012. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer. 
©(2012)(Jozwik and Carroll, 2012) 
 
1.3 ER targeted therapies and resistance 
1.3.1 Pharmacological intervention 
The Luminal tumor subtypes account for two-thirds of all tumors and depend on 
estrogens signaling through the estrogen receptor for growth and survival. These 
tumors are therefore amenable to therapeutics that target the estrogen receptor signaling 
axis to reduce rates of recurrence and improve overall survival probability.  
The anti-estrogen tamoxifen, first approved in 1977 for metastatic breast cancer, 
was the first ever targeted therapy to be used in cancer and still remains part of the 
standard of care of today. Its history is also a remarkable story of drug development and 
repurposing. ICI pharmaceuticals developed a series of non-steroidal anti-estrogens in 
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the 1960s to be used as anti-fertility agents. First developed as a post-coital 
contraceptive, ICI 46,474 (tamoxifen) worked well in rat models but in fact showed pro-
fertility traits in humans and development was abandoned. One unique aspect of the 
drug however was the fact that it exhibited anti-estrogen activity on some tissues but 
agonistic activity on others all the while having a very low toxicity profile. Arthur 
Walpole at ICI then enlisted the help of V. Craig Jordan and tasked him with the 
responsibility of identifying novel applications for the failed drug that could be used 
clinically (Jordan and DOWSE, 1976). Jordan was able to confirm that tamoxifen did 
indeed bind the estrogen receptor and could occlude estradiol, effectively acting as anti-
estrogen in the breast(Jordan, 1976; Jordan and Koerner, 1975; Jordan and DOWSE, 
1976). He further showed that the drug delayed the progression of chemically-induced 
mammary tumors in rat models and that continued long-term exposure was necessary 
to control tumor growth. Ultimately tamoxifen became approved for metastatic breast 
cancer in 1977 and later as an adjuvant treatment option in conjunction with 
chemotherapy in 1986(Ingle et al., 1986). Over time the use of tamoxifen became 
approved for more indications and is in now used for all stages of ER+ breast cancer.  
It is now appreciated that ligands exert a continuous spectrum of activity ranging 
from full agonists to antagonists. Furthermore they exhibit cell and tissue specific 
activities by promoting a unique conformation of ER that allows for differential cofactor 
interactions. Indeed the pharmacology of tamoxifen is not only tissue-specific but is also 
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species-specific. In rat models, tamoxifen behaves as an anti-estrogen but in contrast is 
estrogenic in the same mice tissues. As compounds cannot simply be called estrogens or 
anti-estrogens in a broad sense, a new nomenclature has emerged and the term selective 
estrogen receptor modulator (SERM) now describes the pharmacological 
ligands(McDonnell, 2000). Tamoxifen is classified as a SERM and in the context of the 
breast displays an antagonist profile being able to both compete with estradiol and block 
coactivator recruitment, but has agonist profiles in bone, uterus, and the cardiovascular 
system. Next generation SERMS have been developed and overall have more favorable 
tissue profiles (Table 1-1).  In particular, tamoxifen is an agonist in uterus while 
bazedoxifene and raloxifene are antagonists and therefore decrease the risk of uterine 
hyperplasia(Delmas et al., 1997; Smith et al., 1975). While next generation SERMs have 
less unfavorable effects and better agonist profiles to preserve the beneficial aspects of 
ER in certain tissues, drug development is always in search of the “perfect SERM” to 
delay breast growth,  prevent uterine and endometrial hyperplasia,  ameliorate hot 
flashes,  and improve bone density. 
Table 1-1: Tissue agonist profile of common SERMs. 
 Breast Uterus Bone Vasculature Brain 
Estradiol ++ ++ ++ ++ ++ 
Tamoxifen - + + + - 
Raloxifene - - + + - 
Bazedoxifene - - + + - 
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Another class of ligands exist for clinical use and are known as selective estrogen 
receptor down-regulators (SERDS). Fulvestrant (ICI 182780) is FDA approved for 
metastatic breast cancer and is indicated for post-menopausal women following first line 
anti-estrogen therapy(Howell et al., 2001; Howell et al., 2004; Howell et al., 2002; 
Osborne et al., 2002). Fulvestrant exhibits no partial-agonist activities, has higher affinity 
than tamoxifen, and promote ER degradation. However, the downside to ‘pure anti-
estrogens’ like Fulvestrant is that they also counteract the positive effects of estrogens on 
bone mineral density and other estrogen-dependent tissues. Lastly utility of Fulvestrant 
in the clinic is hindered by its poor pharmacodynamics. 
 Rather than intervening at the receptor directly, the ER signaling axis can also be 
disrupted by reducing the concentration of the endogenous ligand estradiol.  The final 
step in the synthesis of estrogens requires aromatase/CYP19A1 and uses testosterone or 
androstenedione as a precursor(Simpson et al., 1994). Thus aromatase inhibitors (AIs), 
such as examestane, anastrozole, and letrozole are available for clinical use and lead to 
more favorable outcomes in post-menopausal patients(Chia et al., 2008; Winer et al., 
2005). Similar to SERDs, AIs are contraindicated in pre-menopausal patients and lead to 
a decrease bone mineral density.   
1.3.2 Endocrine resistance in the clinic 
Although tamoxifen reduces recurrence breast cancer rates by nearly 50%, 
approximately one-third of patients relapse within 15 years (Early Breast Cancer 
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Trialists' Collaborative, 2005), a finding that highlights the need for clinical assays to 
stratify patient response. As tumor classifications have evolved it is now clear that there 
are sub-classifications that further discriminate response and reflect biological outcomes 
to all classes of anti-estrogens.  It has only recently been appreciated that Luminal B 
tumors differ considerably with Luminal A in their response to tamoxifen and that 
certain sub-classifications of each can be teased out with high success rates to a 
particular therapy (Cheang et al., 2009). In a cohort of 976 patients, the 10-year relapse-
free survival rates for tamoxifen treated Luminal A patients was 70% and contrasted 
with 53% for Luminal B patients(Cheang et al., 2009). Another study was able to identify 
a subset of Luminal A patients with 95% survival probability (Nielsen et al., 2010). 
Building on the premise of distinct expression profiles driving a particular 
phenotype of interest, several multi-gene tests are now available for clinical use to 
stratify risk and predict therapeutic value of treatment options. Thus, genomic efforts 
now provide the opportunity to inform treatment decisions in a molecular subtype-
dependent and gene-dependent manner. The 2013 St. Gallens international breast cancer 
conference touched upon the use of multi-gene signatures to further differentiate the 
Luminal class of patients and supported their use for both prognostic and predictive 
purposes (Goldhirsch et al., 2013; Goldhirsch et al., 2011). Of these, the OncotypeDX 
recurrence assay is FDA approved and the most widely used commercially available 
prognostic test available for node-negative estrogen receptor positive patients (Paik et 
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al., 2006). By analyzing the relative expression of 21 genes it aims to assist clinicians in 
predicting the likelihood of recurrence as well as the benefit of endocrine therapy given 
alone or in conjunction with systemic chemotherapy.  
 Other clinically available tests include MammaPrint dx (van't Veer et al., 2002), 
PAM50(Parker et al., 2009), and Theros Breast Cancer Gene Expression Ratio Assay(Ma 
et al., 2004). The last is derived from the ratio of HoxB13 to IL17BR (HI) otherwise 
known as the Two Gene Index, where high expression of HoxB13 relative to low 
expression of IL17BR is predictive for shortened time to recurrence and tamoxifen 
therapy failure. Conversely, a low ratio is indicative of positive outcome and therapy 
success. Compared to Mammaprint, which contains 70 genes, and OncotypeDX with 21 
genes, the Two Gene Index is surprisingly accurate in predicting responders to 
tamoxifen and disease outcome.  
1.3.3 Mechanisms of endocrine resistance 
Even though tamoxifen has remained a mainstay as a breast cancer therapeutic, 
resistance remains a significant issue as many patients are innately resistant to the drug 
and others acquire resistance during the course of treatment.  Innate resistance is 
characterized by tumors that fail to respond to hormone therapy from the onset of 
treatment and is typically associated with low ER levels or a loss of ER dependency as a 
dominant growth pathway. Acquired resistance is multifactorial and an overview of the 
literature reveals mechanisms centered around growth factor receptors and their 
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signaling cascades that converge on coregulators or directly on ER (Osborne et al., 2003). 
Importantly, ER remains a viable drug target in acquired resistance. Patients that fail 
tamoxifen as a first line therapy historically have good response rates to AIs or 
Fulvestrant (Dodwell et al., 2006; Robertson et al., 2003).  
The ER signaling pathway overlaps with receptor tyrosine kinase (RTK) 
activities. This is due to overexpression or enhanced activation of the RTKs in the cancer 
setting. Xenograft studies have revealed a significant impact of EGFR members on 
tamoxifen response. (Arpino et al., 2007; Massarweh et al., 2008).  Consistent with the 
observation of an increased role of growth factors, serine 118 on ER is phosphorylated in 
response to HER2 activity and this modification clinically associates with tamoxifen 
resistance (Chen et al., 2013; Yamashita et al., 2008). 
Other mechanisms of resistance are focused on coregulators, particularly, SRC3 
(AIB1 or NCOA3). Increased levels of this coactivator correspond with decreased 
antagonism of tamoxifen and also represent a HER2-mediated target of phosphorylation 
(Osborne et al., 2003).  Co-expression of SRC3 and HER2 also predict poor response. In 
another study, PAX2 was found to compete with SRC3 for binding to the HER2 
promoter and expression of PAX2 correlated with good prognosis(Hurtado et al., 2008).  
Other clinical associations of resistance have been elucidated for which there is 
little to no mechanistic evidence currently available. Among these, is the aforementioned 
role of HOXB13 in predicting tamoxifen failure. First discovered using microarray 
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expression data from primary biopsies of ER+ patients treated with tamoxifen 
monotherapy, HOXB13 was found to be differentially expressed between patients who 
relapsed and those that remained disease-free at the five year follow-up(2004; Ma et al., 
2006; Ma et al., 2004). Despite the abundant evidence as an associative biomarker, a 
causal role for HOXB13 in breast cancer pathogenesis has not yet been established. 
Understanding the mechanisms that facilitate resistance to tamoxifen and other ER-
directed therapies will aid in uncovering the biological determinants of response and 
will provide a much needed impetus for rational drug design and in tailoring individual 
therapies to those that will benefit the most.  
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2 Identification of the DNA-dependent, ER associated factors 
in tamoxifen resistance.  
2.1 Introduction 
The estrogen receptor is a master transcriptional regulator in the breast where it 
plays key roles in the development and maintenance of normal breast epithelium but is 
also critical to the growth of luminal breast cancers. Anti-estrogens, such as tamoxifen, 
are used clinically to impede the actions of ER and delay disease progression. Despite 
the initial benefits of tamoxifen therapy, nearly one-third of luminal breast cancer 
tumors eventually become resistant, limiting the therapeutic utility of the drug. While 
resistance  was initially considered to represent a by-pass of ER signaling and reliance 
on alternate growth pathways, there are now several lines of evidence that ER remains a 
viable target and can be inhibited by other ER-targeted therapies to delay progression in 
a large percentage of tumors (Dodwell et al., 2006; Howell et al., 2001; Robertson et al., 
2003). In line with this, ER is found to be expressed at high levels in 80% of metastases 
(Harrell et al., 2006). Collectively, these data indicate that the ER program is central to 
the growth of these tumors and that adaptive mechanisms feedback and converge with 
ER to allow for continued activation.  
To enable the study of relevant mechanisms of resistance, our lab has generated 
an in vivo derived tamoxifen resistant (TamR) model by serial passage of an MCF7 
xenograft tumor in a nude xenograft model under continuous tamoxifen treatment 
(Connor et al., 2001). The TamR model is stimulated by tamoxifen in vivo and does not 
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require estradiol for growth. More importantly, the growth of these tumors is still 
ablated by the pure anti-estrogen, ICI, and also with the second generation SERM, 
bazedoxifene, closely reflecting the clinical resistance setting (Wardell et al., 2013). 
Moreover, ER signaling is very robust and many classical ER target genes are 
dramatically increased, contrary to in-vitro derived models that typically lose ER 
expression. Thus, this model provides an experimental model that can be manipulated 
and evaluated in vitro to explore mechanisms of resistance in breast cancer. 
2.1.1 Genomic evaluation of ER  
Consistent with the idea of an ER-centered mechanism of resistance, ChIP-Seq of 
patient tumor samples revealed that progression and resistance is accompanied by a 
redistribution of ER binding sites (Ross-Innes et al., 2012a). Furthermore, motifs 
enriched around these ER binding sites associated with resistance suggest a role for 
pioneer factors in mediating the reprogramming. Specifically, GATA3 sites were 
indicated to be relatively lost in resistance and motifs rich in PAX2, AP-1 and FOXA1 
were abundant in the tamoxifen-resistant set of ER binding events.  These results are 
intriguing because it suggests that adaptive mechanisms may work at the level of 
chromatin accessibility and also of factors that permit chromatin remodeling for ER 
binding, an idea largely unstudied in drug resistance and particularly for tamoxifen 
resistance.  
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A major challenge in understanding the complexities of the ER signaling 
program is in defining receptor occupancy and the coordinated relationship with 
chromatin architecture and collaborating transcription factors.  In order to fully 
elucidate the regulatory factors that permit ER to bind to novel regions on chromatin in 
the setting of drug resistance, candidate factors would each have to be subjected to 
Chromatin IP followed by deep sequencing (ChIP-Seq) which limits throughput and 
confines the experiment to factors known a-priori.  Alternatively, regulatory elements 
and associated motifs can be identified in an unbiased manner using DNase-I 
hypersensitivity analysis (Galas and Schmitz, 1978).  The enzyme, DNase-I takes 
advantage of chromatin dynamics and preferentially cleaves open chromatin at labile 
sites to map active regulatory elements. Open chromatin regions are referred to as 
DNase-I hypersensitive sites (DHSs) and are traditionally viewed as sites with 
nucleosome depletion due to transcription factor binding(Gross and Garrard, 1988).  
By coupling DNase-I hypersensitivity analysis with modern technologies such as 
microarrays (DNase-chip) or high-throughput sequencing (DNase-Seq), genome-wide 
views of chromatin accessibility can be obtained (Boyle et al., 2008a; Crawford et al., 
2006).  Consequently, active regulatory elements including promoters, enhancers, 
silencers, insulators and locus control regions can be identified globally (Boyle et al., 
2011; Cockerill, 2011; Heintzman et al., 2007).  As part of the ENCODE project, DNase-
Seq profiles of 125 human cell lines were characterized and integrated with mRNA 
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expression, DNA methylation, chromatin conformation and transcription factor binding 
sites (Consortium, 2012; Thurman et al., 2012). Collectively, these data reveal that DHSs 
are often distal to associated promoters, correlate strongly with transcription factor 
binding, are embedded in histone modified regions and cluster with similar cell-types. 
Additional studies have elucidated cell-specific DHS profiles and that  distal interactions 
predominately control cell identity, while DHSs ubiquitous among cell types are located 
proximally to transcription start sites (Gertz et al., 2013; Sheffield et al., 2013; Song et al., 
2011b).  The binding of a transcription factor to DNA protects local chromatin from 
DNase-I cleavage and leaves a border of heightened cleavage on the periphery to 
produce a ‘footprint’. Digital genomic footprinting via DNase-Seq leverages this concept 
to predict occupancy and factor identification through associated motifs in a single 
experiment at single nucleotide resolution (Hesselberth et al., 2009; Neph et al., 2012).   
The methodology of DNase-Seq has been used previously to delineate the 
actions of nuclear receptors ER and AR with respect to their cognate ligands, and 
showed strong correlation to occupancy as determined by ChIP-Seq  (He et al., 2012; 
Tewari et al., 2012). These studies also revealed critical differences in the binding 
properties of these two receptors. ER predominately binds to regions of partially open 
chromatin, induces further opening with ligand activation and does not promote 
nucleosome remodeling to a large extent. Furthermore, DHS sites alone are good 
predictors of ER binding and the precision of identifying a true ER binding site is 
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dramatically increased with the intersection of DHSs and motifs. In comparison, AR 
binds to both “poised” and closed chromatin regions with a concordant change in 
nucleosome positioning.  In the course of the present study, a report was published that 
compared the ER chromatin landscape and ER binding sites across two distinct, 
estrogen-sensitive cell lines of breast and endometrial origin (Gertz et al., 2013). Overall, 
the study concluded that strong affinity motifs for ER are generally conserved binding 
regions and that ER is capable of remodeling the chromatin at these regions to a larger 
extent than locations with weak affinity motifs. Moreover, the cell-specific ER binding 
sites exhibited weak motifs but were likely available for binding due to the presence of 
juxtaposed cell-specific factors that bookmarked chromatin to maintain an active open 
state.  
Therefore, the global approach of DNase-Seq is well-suited to identify ER 
collaborating and associated DNA-bound factors that inform novel ER binding profiles. 
While precedence of ER actions across cell lines and response to ligand has been set, the 
molecular mechanisms that underlie tamoxifen resistance are scarcely studied on the 
level of chromatin and demand attention. Elucidation of these features will improve 
patient outcomes by further stratifying risk, will enable clinicians to make better-
informed decisions in regards to therapy, and hold the potential to inform novel drug 
development programs. To this end, we undertook the present study to investigate the 
consequences of chromatin architecture and transcription factors in tamoxifen resistance 
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and with the intent of identifying and characterizing factors as they relate to ER 
function. 
2.2 Results 
2.2.1 DNase-Seq identifies an increased role for FOXA family 
members in a cellular model of tamoxifen resistance. 
2.2.1.1 DNase-Seq on sensitive and resistant cell lines 
To assess the relationship between accessible chromatin and the ER signaling 
program we performed DNase-Seq on a tamoxifen resistant cell line (TamR) and a 
comparator group of two closely related tamoxifen sensitive cell lines: MCF7 and a 
subline of MCF7 that has been adapted for xenograft growth conditions named 
MARCO. Two independent biological replicates of MCF7 cells (sensitive), MARCO cells 
(sensitive) and TamR cells (resistant) were plated in charcoal stripped serum for 48 
hours and then treated with vehicle or  4-hydroxytamoxifen (4-OHT) at 100nM for 24 
hours. Using previously published methodologies from the Crawford Lab (Boyle et al., 
2008b), libraries were prepared and submitted for 50bp SR Illumina sequencing on the 
HiSeq platform at Duke resulting in an average of 70 million unique mapped reads per 
sample (Table 3-1). Additional details of data processing and filtering are available in the 
materials and methods.  
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Table 2-1: Overview of sequencing libraries and reads. 
Cell Line Treatment Replicate Unique Mapped Reads 
MCF7 Vehicle 1 67,199,476 
MCF7 Vehicle 2 68,986,891 
MARCO Vehicle 1 85,401,169 
MARCO Vehicle 2 76,555,399 
TAMR Vehicle 1 75,331,103 
TAMR Vehicle 2 63,442,543 
MCF7 4-OHT 1 60,291,199 
MCF7 4-OHT 2 70,235,124 
MARCO 4-OHT 1 74,614,947 
MARCO 4-OHT 2 76,358,470 
TAMR 4-OHT 1 62,928,784 
TAMR 4-OHT 2 69,496,954 
 
 DNase-I hypersensitive sites (DHSs) were defined using the peak caller F-SEQ 
which uses a kernel density estimation procedure appropriately suited for the 
background distribution of DNase-Seq data(Boyle et al., 2008b). Taking the union set 
(full outer join) of DHSs from every condition, 508,533 sites in total were defined 
representing 4.3% base coverage of the genome. Peaks falling within +/- 500bp of the TSS 
were also separated to distinguish between general transcriptional effects and bona fide 
TF binding. The number of sequence reads that mapped to each feature of the union set 
of DHSs was quantified and differential testing was performed using DESeq(Anders 
and Huber, 2010) in R/bioconductor with a significance threshold of p < 0.01.   
The number of changes due to (4-OHT)-(Veh) in any of the cell lines was quite 
modest--typically less than 50 DHSs being statistically different. It has been previously 
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reported that tamoxifen induces DNA binding in a similar manner to E2 but at much 
lesser a degree in a short time frame and only in a subset of regions, and so it was not 
surprising that the number of changes in MCF7 cells were insignificant at 24 hours.  On 
the other hand, there were dramatic differences between any two cell lines in the 
untreated state. This was intriguing because these cell lines are of the same genetic 
origin and the differences likely represent the divergent phenotypes they display in 
response to 4-OHT. Comparing the sensitive group to resistant TamR cells under vehicle 
treatment, 7,399 DHSs were identified as significantly different.  Among these, 82% or 
6,016 DHSs have an increased signal in TamR cells and 18% or 1,383 DHSs are decreased 
(Figure 2-1). 
 
Figure 2-1: Differential DHS sites between cell lines. 
Differential DHS sites between cell lines. (A)Table of the number of sites identified as 
significantly differential by DESeq with p< 0.01 for each testing condition. (B) Track view of 
CAV1 locus and continuous DNase-Seq signal in MCF7(Blue), MARCO(Red) and 
TamR(Green). (C) Circos map of the whole-genome distribution of significant DHS sites from 
TamR relative to MCF7. A normal karyotype ideogram is shown on the outside. Inner layer is a 
scatter plot of the log2 fold change from DESeq. Green=up in TamR, Red=down in TamR for 
each DHS. 
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While each tested differential condition likely epitomizes the biological features 
unique to each cell type along with the resistant mechanisms, the multi-factorial 
condition of (Resistant-Sensitive) was chosen for downstream analyses. This condition 
represents the compilation of sites that are both necessary and sufficient for the resistant 
phenotype and is a more conservative approach than comparison against either of the 
two sensitive cell lines independently. The 7,399 sites of (Resistant-Sensitive) and 
relative differences in DNase signal across cell lines is visualized in Figure 2-2.  
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Figure 2-2: Plots of significant DHS sites. 
Plots of significant DHS sites. (A) Heatmap of DNase signal in a 10kb window of 7,399 
significant different DHSs between sensitive and resistant cells. Each row is centered on an 
individual DHS site and data is clustered using k-means.  (B) Histogram of the 6,016 DHS sites 
that are more open in TamR cells. (C) Histogram of the 1,383 DHS sites that are more closed in 
TamR cells.  
 
  We also compared the distribution of DHSs relative to genomic features (3’ 
UTR, 5’ UTR, CpG-Islands, Distal, Exon, Intron, Promoter, Satellite, and TTS) as both an 
absolute number and additionally by the relative enrichment when normalized by DNA 
content. Even though intron and distal sites are more represented overall, they are not 
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nearly enriched compared to CpG-Islands or promoters, which relatively contain more 
DHSs when size of the feature is taken into account. Compared to all DHSs, the 7,399 
significant set of significantly differential DHSs was similar in trend with minor 
differences. The differential DHS sites were even more enriched in intron and distal 
features, indicative of transcriptional enhancers (Figure 2-3). 
 
Figure 2-3: Distribution of DHS sites. 
Plots representing the distribution of DHS sites in each genomic feature for (left) all DHS sites 
from the union set and (right) differential DHS sites from (Resistant)-(Sensitive). Bar colors 
represent the relative enrichment of features normalized to DNA content.  
 
2.2.1.2 Motif Enrichment Analysis 
A major objective of these studies was to identify the DNA-bound factors with 
differential binding profiles in resistance.  Therefore, differential DHSs for (Resistant)-
(Sensitive) were interrogated for motif enrichment analysis with a two pronged 
approach to minimize bias. It’s important to note that of the ~2000 identified 
transcription factors, only a few hundred have high quality motifs mapped and de novo 
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motif finding is essential to identifying the factors involved (Vaquerizas et al., 2009). 
Motifs were identified using a local installation of MEME-ChIP (Machanick and Bailey, 
2011) with a “zoops” model for motif finding with a focus on the number of hits relative 
to background, high percentage of hits, and central distribution of the motif within the 
DHS sites. Parallel to this approach, motif finding for factors with known motifs and de-
novo motif finding was also performed using Homer (Heinz et al., 2010) (Table 3-2). 
Several factors were coincident among all motif finding methods and best matched 
known motifs for AP-1, AP-2, FOXA, ELF5, ER, and TEAD families. Discordant motifs 
were also found and most closely resembled IRX5, GRHL2, KLF4, MED-1, SPDEF and 
ETS family members.  
 
Table 2-2: Table of high confidence de-novo motif finding results from Homer 
for sites increased in DHS signal. 
Rank P-value % of 
Targets 
% of 
Background 
Best Match/Details 
1 1e-464 18.53% 3.37% Jun-AP1(bZIP)/K562-cJun-ChIP-
Seq/Homer 
2 1.00E-246 24.19% 9.39% AP2gamma(AP2)/MCF7-TFAP2c-ChIP-
Seq/Homer 
3 1.00E-186 19.63% 7.81% FOXA1(Forkhead)/MCF7-FOXA1-ChIP-
Seq/Homer 
4 1.00E-158 21.78% 9.99% PH0086.1_Irx5/Jaspar 
5 1.00E-143 23.15% 11.42% ELF5(ETS)/T47D-ELF5-ChIP-
Seq(GSE30407)/Homer 
6 1.00E-95 21.73% 12.14% TEAD4(TEA)/Tropoblast-Tead4-ChIP-
Seq(GSE37350)/Homer 
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Motifs were also elucidated for sites that decrease in DNase signal in TamR cells. 
The number of sites used for querying was lower in this group but motif enrichment 
analysis still yielded a strong hit for CTCF and weakly associated motif for AP-1 and 
AP-2.   
Motifs matching all criteria for inclusion as outlined above, in both increased and 
decreased sites, are represented in Figure 2-4. 
 
Figure 2-4: Identified motifs in differential DHS sites. 
 
2.2.1.3 Comparison with mapped binding sites. 
One important limitation of relying on motifs for identification is that DNA 
sequence is not the sole determinant of transcription factor occupancy. Even though 
motif enrichment procedures have merit, direct evidence of factor binding is often more 
reliable. Therefore, to supplement our motif analysis, we additionally downloaded and 
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processed publicly available ChIP-Seq and ChIP-exo data for breast cancer cell lines 
(GSE25710, GSE48930, GSE40129) and ENCODE factors (GSE32465, GSE31477), to 
identify co-enriched binding profiles. Binding coordinates for each factor were analyzed 
to identify overlapping profiles and correlation of co-localization for every factor pair, 
generating a large correlation matrix of Spearman’s coefficients. This data was then 
clustered and visualized as a heatmap (Figure 2-5). The regions of increased DNase 
signal (DNase_Up) clustered most strongly with FOXA1 regions and secondarily with 
ER, closely mirroring the outcomes from the motif analysis. Regions of decreased DNase 
signal clustered with CTCF and RAD21, again coinciding with the motif finding results. 
One shortcoming to these analyses is that not all factors identified by motif analysis have 
global binding data and thus cannot be evaluated by this approach. Another caution is 
that multiple cell lines are represented and may not be reflective of the de facto binding 
sites of cells used in our studies. 
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Figure 2-5: Heatmap of binding profiles. 
Heatmap representation of the clustering of different transcription factors binding coordinates and 
their correlation to sites with increased signal (DNase_Up) and decreased signal (DNase_Dn). 
 
Given the preponderance of evidence that FOXA1 and other pioneer factors 
cooperate with ER and co-localize on DNA, we also performed differential binding 
analyses to identify regions where factors uniquely exist (factor-unique sites) and where 
they overlap with other factors (factor-shared) to better elucidate each factor’s 
contribution. As a binary example, FOXA1 has 70,915 known binding sites while ER has 
21,700. These two factors coincide at 9,580 sites, leaving 61,335 FOXA1-unique sites and 
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12,120 ER-unique sites. Each factor-unique subset of binding sites can then be compared 
with the DNase data for evidence of factor enrichment in TamR cells (Figure 2-6). These 
data substantiate a role for FOXA1 on both ER-independent sites and ER-dependent 
sites and bear further evidence that known ER-unique sites (devoid of FOXA1) are 
unaffected in TamR cells.  
 
Figure 2-6: Differential binding profiles for ER and FOXA1. 
Schematic representing factor-unique profiles for both ER and FOXA1. Venn diagram of ChIP-
Seq biding sites with overlap (above). Histograms for each factor-unique subset (below).  
 
As there is considerable overlap with ER, FOXA1 and GATA3, unique binding 
profiles of each can also be derived in this context. Without such subsets, GATA3 and 
other factors show apparent enrichment with DNase signal, but when FOXA1 
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overlapping sites are removed, the apparent increase is mitigated. In this manner, 
several interesting factors were profiled: GATA3, AP-2gamma, CTCF, TCFL2, and PBX1 
(data not shown). These results largely corroborated the motif enrichment results and 
highlighted both AP-2gamma and CTCF as factors that are lost in the intermediate, yet 
sensitive MARCO lineage which may represent a necessary but insufficient step in 
tamoxifen resistance.  
2.2.1.4 Footprint analysis of top factors 
Evidence of a well-defined footprint for a specific factor in differential DHS sites 
is another method to verify motif results and prioritize the number of possible 
candidates. In comparison to correlation of ChIP-Seq data, footprint analysis can 
additionally account for de novo binding sites which are not present in MCF7 cells. For 
this purpose, genome-wide motifs were identified with a strict log odds ratio and only 
sites that overlapped with differential DHS regions were used for analysis.  
Among the 6,016 differential DHS sites, 4,295 high confidence motifs for FOXA1 
were identified. Sequencing tags were quantified relative to motif start site in a strand 
specific manner and plotted as a histogram at single base pair resolution (Figure 2-7). 
TamR cells are highly enriched in DNase signal in these regions, similar to Figure 2-2B, 
and more importantly exhibit a strong footprint central to the distribution of the data. 
Moreover, the characteristic footprint observed in the differential DHS sites is consistent 
with the footprint obtained from the union set of DHS sites.  
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Figure 2-7: Footprint analysis of FOXA1. 
Aggregate profiles of DNase signal relative to FOXA1 motifs. (A) Histogram of increased 
differential DHS sites across a 1.5kb window. (B) Same data as in A, but view is focused on 50bp 
each direction of FOXA1 motif. (C) FOXA1 footprint in the union set of DHS sites.  
 
The number of confident ER motifs in the increased DHS sites was much smaller 
due to motif degeneracy with 635 sites, yet an enrichment of signal in TamR cells was 
observed in addition to a palindromic footprint. Intriguingly, there was also a noticeable 
difference of base pair dependency in the central degenerate linker region of the two half 
sites, suggesting additional contacts of stabilization specific to ER in TamR cells.  
In this manner, top motifs were profiled by footprint analysis. The association of 
AP-2 to differential sites was also noteworthy with strong relative enrichment and 
associated DNase protection at the central motif region but was not as robust as FOXA1. 
 
2.2.1.5 Correlation with resistant-specific ER binding sites. 
In order to evaluate the relevance of the TamR model in resistance we relied on a 
previously published study that found differential binding of ER in patients exhibiting 
resistance to tamoxifen(Ross-Innes et al., 2012b). The study specifically identified 448 
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sites unique in resistance and the DNase data from our study showed similar trends of 
increased DNase signal at these resistant-specific regions (Figure 2-8). 
 
Figure 2-8: Comparison of DNase data with 448 sites found in tamoxifen 
resistance. 
The 448 of ER binding sites unique in tamoxifen resistance were profiled for their relationship 
with the DNase data in MCF7, MARCO and TamR cellular models. (A) Heatmap of DNase-Seq 
data at 448 binding sites where TamR DNase intensities are ranked from high to low. (B) 
Aggregated histogram of the same data. 
 
2.2.2 Increased occupancy of FOXA1 and ER in TamR cells. 
FOXA1 emerged from the motif enrichment, footprint analysis and ChIP-Seq 
comparative analyses as a likely candidate to occupy regions within differential DHS 
sites. To validate a biological role for FOXA1 and associated binding of ER to these sites, 
ChIP-qPCR was performed at 15 candidate loci. Primer sequences are available in 
 47 
materials and methods. Four of these sites are presented in Figure 2-9. Two of these sites 
are ER-independent, AGR2 enhancer 2 (AGR2-2) and WISP1 enhancer 2 (WISP1-2), 
while S100A9 enhancer 2 (S100A9-2) and XBP1 enhancer 3 (XBP1-3) are both ER-
dependent and FOXA1-dependent. These data clearly highlight an enhanced 
recruitment of FOXA1 to these sites and also enhanced binding of ER at ER-dependent 
sites. The level of ER occupancy at these two loci also reveals that ER binding is maximal 
in TamR cells under basal conditions and there is little enrichment with E2, contrasting 
the role of ER in MCF7 cells.  
 
Figure 2-9: ChIP-qPCR of ER and FOXA1.  
Occupancy of ER and FOXA1 was analyzed in MCF7 and TamR cells treated with ether 
vehicle(V), 10nM estradiol(E) or 100nM 4-OHT(T) for 45 minutes. Cells were cross-
linked and immunoprecipitated with either control IgG, ER or FOXA1 antibodies. All 
data is represented as the percent input from total chromatin. 
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2.2.3 Characterization of FOXA1 and ER function in TamR cells 
To substantiate the role of increased FOXA1 signaling and its effects on ER, 
robust activated targets of FOXA1 were assessed by qPCR. In these experiments we used 
siRNA directed against FOXA1 in combination with ER ligands to understand the role 
of each factor on these genes. These approaches are far from comprehensive and are not 
meant to elucidate every gene and its regulation by these factors, but rather to verify a 
role for FOXA1 on ER targets.  The qPCR data is presented as a heatmap in Figure 2-10. 
These data indicate that of the FOXA1 targets profiled, expression is relatively increased 
in TamR cells and remains sensitive to siFOXA1 ablation. Furthermore, these genes are 
comparatively insensitive to E2 in TamR cells but using the pure anti-estrogen ICI, gene 
expression is inhibited on some genes suggesting that certain subsets are more 
dominated by FOXA1 while others require both FOXA1 and ER for complete activation. 
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Figure 2-10: Heatmap of FOXA1 activated targets. 
Heatmap of mRNA expression of FOXA1 target genes as determined by qPCR. Cells were 
reverse-transfected with control siRNA (siLuc), and two siFOXA1(siFOXA1_C, siFOXA1_B) 
for 72 hours and then induced with E2 for 24 hours prior to harvesting. Data points are a 
represented as delta delta Ct values from the mean of triplicate experiments.  
 
 
TamR cells also reflect increased FOXA1 activity on FOXA1 repressed genes: 
ANXA1, KLK6, WISP2, and S100A9.  A large percentage of the FOXA1 repressed genes 
are also induced by ER in MCF7 cells, and the regulation of these genes are divergent in 
TamR cells.  In MCF7 cells, both mechanisms are intact and activation by ER requires 
FOXA1 while FOXA1-mediated repression is independent of ER. This tug of war 
phenomenon results in a class of genes that are driven by ER and upregulated, and a 
second class of genes that are further repressed by FOXA1 and consequently 
downregulated in TamR cells (Figure 2-11). As an example, KRT13 can be induced by ER 
while siFOXA1 de-represses gene expression, meaning both mechanisms are intact in 
MCF7 cells. However, TamR cells have lost FOXA1-mediated repression of this gene 
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and its regulation is instead dominated by ER leading to a large increase in gene 
expression (Figure 2-11). In the other class, WISP2 is both ER-activated and FOXA1-
repressed in MCF7 cells but is dominated by the FOXA1 repression mechanism in TamR 
cells.  
 
Figure 2-11: FOXA1 repressed genes. 
Two distinct classes of FOXA1 repressed genes are present in TamR cells. (A)Overall gene 
expression across cell types for both KRT13 and WISP2. (B) Expression in MCF7 cells with 
control siLUC or two siRNAs of FOXA1. (C) Expression in TamR cells with control siLUC or 
two siRNAs of FOXA1. 
 
2.2.4 Identification of FOXA1 interacting partners 
It was observed that the overall protein levels of FOXA1 was not significantly 
different between MCF7 and TAMR cells, and therefore we hypothesized that the 
activity of FOXA1 was being modified by either an epigenetic mechanism or by other 
factors modifying and/or binding to FOXA1. To address the latter hypothesis, we 
performed a set of experiment to identify PTMs and interacting partners of FOXA1 by 
 51 
using Mass Spectrometry. To this end it was necessary to chemically crosslink the 
antibody to agarose beads with DMP permitting co-immunoprecipitation (CoIP) 
experiments without eluting large contaminating IgG fragments. These experiments 
were performed in MCF7 and TamR cells in normal FBS conditions. Nuclear extracts 
were isolated and normalized to 10mg of protein for each and immunoprecipitated with 
control IgG and FOXA1 antibodies cross-linked to A/G beads. Washing conditions were 
optimized to efficiently remove non-specific proteins while maintaining adequate 
FOXA1 levels. Eluted fractions were submitted to the Duke Proteomics Core and LC-
MS/MS was used to identify putative FOXA1 interacting partners and separately to 
identify PTMs of FOXA1. These runs resulted in identification of a total of 229 high-
confidence proteins with 1% FDR, of which 23 of these are putative binding partners of 
FOXA1 in other cell types.  Interestingly, two of the factors identified by CoIP were also 
identified by motif analysis above, namely AP-2 and GRHL2 (Figure 2-12). HDAC1 and 
SIN3A were also specifically found in the TamR subset and may indicate that 
corepressor complexes have an increased role in the FOXA1 signaling paradigm in 
TamR cells. A network plot and table of interactors is presented later in this chapter. 
Approximately 40% sequence coverage of FOXA1 was achieved, which is as much as 
could be expected with trypsin digestion. Of the modifications identified, only a 
phosphorylation site at S331 was found to be differential, with it preferentially being lost 
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in TamR cells. Studies are currently underway with GRHL2 to understand if and how it 
participates in FOXA1 signaling.  
 
Figure 2-12: Mass-Spec identifies putative interacting partners. 
Of the 229 identified proteins, 91 proteins were found specific to FOXA1 in TamR cells. Among 
these two were also identified from motif enrichment analysis in 1.2.1.2. Motif results (below) are 
the outputs from the MEME Suite and include identified motif, distribution in differential DHS 
sites and significance score.   
 
In the course of doing the CoIP experiments it was observed that FOXA1 
partitions between the nuclear and cytosolic compartments and shuttles depending on 
the growth conditions of the cells. This partitioning is enhanced in FBS and FOXA1 
levels are more enriched in the nuclear compartment in TamR cells. In addition to 
partitioning, the size of FOXA1 is slightly shifted upward on the gel in the nuclear 
extract samples, possibly reflecting a PTM induced mobility shift or the size difference 
could also be due to cleavage of the protein product in the cytosolic extracts. Mass-spec 
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analysis of the protein only had 40% coverage and so we could not confidently map all 
regions to identify specific modifications. Therefore, to determine if phosphorylation of 
FOXA1 was responsible for the upshift, we incubated the prepared samples in lambda 
phosphatase and while the control samples had mobility reversed, the FOXA1 samples 
were unchanged indicating the shift was not due to phosphorylation. FOXA1 pulldowns 
were also performed and immunoblotted with phosphorylation and acetylation 
antibodies for presence of these modification with no success. At present there is no 
evidence to explain these results.  
2.2.5 Integrative analysis with mRNA expression 
Genome-wide expression was also performed on the MCF7, MARCO, and TamR 
cells with vehicle or 4-OHT for 24 hours with RNA-Seq. These treatment conditions 
were identical to the DNase-Seq data but were performed at different times and in 
independent cell passages. Reads from 50bp paired-end Illumina HiSeq were aligned to 
the human reference genome hg19. Concordant read pairs were then quantified over 
Ensembl transcripts and differential expressed transcripts were identified using 
edgeR(Robinson et al., 2010). Differential transcripts were identified for (4-OHT)-(veh) in 
every cell type and a general linear model was defined to identify the multifactorial 
condition of interaction of response (sensitive and resistant) and treatment (vehicle or 4-
OHT). The differential condition, (Resistant_veh)-(Sensitive_veh), is used for 
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downstream integrative analysis and relates to the DNase-Seq data (Resistant-Sensitive) 
outlined above.  
Pathway analysis on the differential transcripts was performed with GSEA and 
resulting enriched gene-sets were organized into a topological similarity network 
(Figure 2-13). 
 
Figure 2-13: GSEA enrichment map. 
A similarity network of GSEA results, where nodes represent gene-sets, and edge length 
represents similarity of the genes between the gene-sets. Size of the nodes indicates the number of 
genes within a gene-set and color of the node reflects the normalized enrichment score. Red is 
positively correlated with resistance and blue is negative correlated. Associated terms were 
derived from the Cytoscape plugin, WordCloud.  
 
 
One way of integrating expression data into the DNase-Seq data is to identify all 
differentially expressed transcription factors and presence, if any, in the identified motif 
enrichment analysis. Expression levels of a factor may be the simplest explanation as to 
how a factor has an increased role in TamR cells. For this purpose, the gene ontology 
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term, 0003700: sequence-specific DNA binding transcription factor activity, was used to 
subset the available significantly differentially expressed genes to a total of 217 TFs. 
Notable, robustly upregulated TFs included : GATA4, FOXA2, NKX2.2, ELF5, TFAP2B 
(AP-2beta), NOTCH1, and STAT6. Downregulated TFs included: SMAD4, PGR, 
SMAD2, ETV5, STAT1, and HOXA10.  
Among these, FOXA2 is of primary interest because it is highly homologous to 
FOXA1, binds to a similar DNA consensus sequence and interacts with FOXA1 as a 
heterodimer (Bochkis et al., 2012). Genetic studies also indicate partial redundant roles 
in liver, foregut and pancreas during development (Gao et al., 2008). In mice knockout 
studies, FOXA1 or FOXA2 deletions had no obvious effect on liver morphology, while 
double knockouts led to complete loss of liver formation (Lee et al., 2005). In our system, 
siRNA against FOXA2 failed to elucidate a role for it in the before mentioned FOXA1 
target genes or on biological assays measuring viability or growth in soft agar (data not 
shown). Nonetheless, we have not yet ruled out a role for it in establishing enhancer 
competency of the de-novo FOXA1 sites. 
Other interesting candidates include ELF5 and AP-2. Curiously, two AP-2 motifs 
were identified with slightly differing binding preferences and one was associated with 
a loss of DNase and the other with a gain of DNase in DHSs in TamR cells. The ChIP-
Seq comparison of AP-2gamma also revealed loss of DNase signal at these sites. In light 
of the fact that AP-2beta is highly upregulated the possibility exists that isoform bias 
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may account for some of the upregulated DHS sites and requires further attention. ELf5 
was also recently reported to suppress the actions of ER in T-47D cells (Kalyuga et al., 
2012). 
Histone modifiers are also of utmost importance given their correlation with 
FOXA1 activity (Lupien et al., 2008). In this case H3K4me1/2 positively correlates with 
FOXA1 binding and activity. Histone modifying genes were subset using the GO term, 
0016570: histone modification, yielding 48 differentially expressed genes. These subsets 
of genes could not explain increase in HAT activity or a loss of a histone demethylase.  
The increase in FOXA1 activity could also be explained through a mechanism of 
coregulator activity by potentially shifting the balance towards activation. Notable 
repressors downregulated include TLE1, RIP140, ID1, ID2, and ID3. The number of 
coactivators is quite large and without knowing exactly which bind to FOXA1 through 
further proteomic techniques, it is difficult to ascertain a model of resistance at this 
point.  
 Lastly, the Mass-Spec revealed binding partners of FOXA1 that are MCF7-
specific, TamR-specific or shared. A network plot of the putative factors was generated 
to visualize the data. Cytoscape was used to color the nodes according to differential 
expression of (Resistance)-(Sensitive) and the outer stroke color of the node to represent 
average expression.  When plotted with expression it is apparent that increased 
differential expression is not a major determinant of association (Figure 2-14).  
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Figure 2-14: Network plot of factors identified by Mass-Spec. 
Cytoscape plot of cell-specific FOXA1 associated proteins.  Nodes are colored according to the 
differential Log2 expression of (Resistance)-(Sensitive) and average expression is indicated with 
the outer stroke color of the node.  
 
2.3 Discussion 
In this study we have identified several transcription programs that are 
differentially active in a cellular model of tamoxifen resistance. In particular, FOXA1 is 
enriched in resistant-specific chromatin accessible loci and regulates target gene 
transcription in both an ER-dependent and an ER-independent manner. The increased 
role of FOXA1 is not due to an increase in total protein levels however and instead is 
manifested through increased activity and potentially by localization.   
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There are multiple independent lines of evidence that ER transcriptional activity 
drives cell growth in endocrine resistance. The ER signaling program is plastic and can 
be reprogrammed in a cellular context by chromatin accessibility, epigenetics, 
coregulators and other transcriptional initiators including pioneer factors. Indeed, ER 
negative cells can be forced to house an ER program if ER and other pioneer factors are 
co-expressed, but not in the context of ER expression alone (Kong et al., 2011a). Since the 
discovery of FOXA1 as both a pioneer factor and implicit member of the ER signaling 
program in breast tissues, additional studies have uncovered several factors with 
reported licensing activity for ER and correlative association in clinical data (Magnani et 
al., 2011; Tan et al., 2011a; Theodorou et al., 2013). While many studies have probed ER 
and co-enriched motifs, evidence of functionality has been lacking.  Furthermore, there 
is currently an absence of evidence as to the role of these ER-associated factors in drug 
resistance or in the role of reprogramming ER in tumor progression. Identification of the 
factors that endow ER with transcriptional competency in a model of resistance 
compared to sensitive cells was the primary focus of this study. Integrative analysis of 
DNase-Seq and enriched motifs with differential binding profiles of dozens of factors 
have elucidated a potential role for FOXA1 in mediating resistance. These results are 
substantiated by a dramatic increase of FOXA1 occupancy at these regions and 
experimental evidence validating a heightened functional role for FOXA1 in adjacent 
target gene transcription.  
 59 
The role of FOXA1 in resistance has been controversial with opposing views in 
the literature. As FOXA1 is essential to the ER signaling program, its expression is 
highly correlated with ER and makes up the minimal definition of a luminal subtype. 
Analysis of tissue microarray first elucidated the correlation of FOXA1with ER and 
association in low grade tumors (Wolf et al., 2007). Subsequent studies confirmed these 
associations in more than 5000 patients. Furthermore, we and others have shown FOXA1 
expression levels of primary tumors to correlate with good prognosis (Badve et al., 2007; 
Thorat et al., 2008). FOXA1 was also found to be a good prognostic marker and that it 
had independent prognostic and predictive ability in line with Oncotype DX 
(Ademuyiwa et al., 2010).  FOXA1 could also be considered favorable because loss of 
which could lead to basal characteristics and worse outcomes (Bernardo et al., 2013); 
underlying the need to selectively inhibit FOXA1.  
On the other hand, FOXA1 binding sites are enriched in regions of novel ER 
binding sites in tumors resistant to tamoxifen (Ross-Innes et al., 2012b) and overlap with 
~50% of ER binding sites total; imparting some control over ER binding preferences. Our 
results also reveal a functional difference of FOXA1 activity in TamR cells compared to 
MCF7 cells and suggests that a switch occurs to allow FOXA1 to take on oncogenic 
functions. One potential means of increased activation may rest on the ability of FOXA1 
to respond to upstream signaling cascades. Phosphorylation mapping of FOXA1 
revealed a loss of phosphorylation at S331 in TamR cells and functionality of this site is 
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currently being tested. In addition, our sequencing results found MCF7 cells to harbor 
the FOXA1 variant S448N, rs33984772, at a low frequency (~10%), but TamR cells carry 
the variant allele at a higher frequency (~58%); suggestive of biological functionality of 
S448. Another report identified FOXA1 to be acetylated by P300 and consequently 
diminishes DNA binding (Kohler and Cirillo, 2010), an event which may be due to 
growth factor signaling (Katika et al., 2013). 
 One interesting aspect to these results is that FOXA1 levels in TamR cells 
do not change and therefore undermines primary testing of FOXA1 levels as a 
prognostic indicator of its activity. In this regard, an activity signature of FOXA1 in this 
context is absolutely required. Using the robust targets of 30 experimentally validated 
target genes of FOXA1, a negative prognostic association of FOXA1 activity on relapse-
free survival and distant-free metastasis is observed, highlighting the need for a 
thorough evaluation of target gene regulation to associate the effect on survival more 
broadly. While the importance of FOXA1 in ER action has been implicated in the clinic, 
the TamR model is the first observation of heightened FOXA1 activity in a model of 
resistance. Despite the scarcity of a FOXA1-mediated role in tumor progression or 
resistance, FOXA1-dependent genes are commonly identified as negative prognostic 
markers and notably include PS2, SPDEF, KRT13, XBP1, and AGR2.  
Targeting FOXA1 in cancer should be approached with caution. As stated before, 
FOXA1 does have a role in maintaining an active ER program and elucidation of the 
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features that allow growth in a resistant state should be meticulously defined to inform 
drug development on the positive and negative facets of FOXA1. As stated before, 
tamoxifen resistant tumors and TamR cells are still sensitive to ER inhibition and 
alternative anti-estrogens inhibit growth. With this in mind, identification of the SERM 
profiles and their intrinsic differences of inhibiting ER on unique subsets within these 
FOXA1 loci is an intriguing approach that could have a real impact on the clinic in the 
near term. Also, an understanding of the SERM profiles in relation to FOXA1 activity 
will elucidate novel biomarkers for tracking progression and inform key molecular 
targets in drug discovery.  
In summary, several independent experimental data and orthologous techniques 
elucidate a novel role for FOXA1 in driving tamoxifen resistance by means of 
reactivation of ER pathways.  Experimental evidence indicates an altered usage of 
FOXA1 localization, modification and DNA occupancy in a tamoxifen resistant model. 
Thus, FOXA1 may be susceptible to modification as tumors progress to resistance.  A 
further understanding of the role of FOXA1 in progression to and maintenance of 
tamoxifen resistance will determine whether this essential factor can be effectively 
targeted to delay tumor progression and improve the efficacy of ER-targeted therapies.  
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3 The role of HOXB13 on breast cancer pathogenesis 
3.1 Introduction 
With the abundance of gene expression data and relatively high rates of 
tamoxifen therapy failure, it’s not surprising that several groups have used gene 
signatures to stratify risk by assessing the predictive value of gene expression on 
therapeutic outcome.  One of these signatures is the two gene ratio of HOXB13:IL17RB, 
where the high expression of HOXB13 relative to a low IL17RB was found to 
differentiate patients that relapsed to those that remained disease-free at the five-year 
follow-up(Ma et al., 2004). More importantly this ratio correlates with poor prognosis, 
shortened time to recurrence, and tamoxifen therapy failure in ER+ breast cancers. The 
significance of the prognostic and predictive value of this ratio has been studied 
extensively and confirmed by multiple investigators in several cohorts of patients (Goetz 
et al., 2006; Habel et al., 2013; Jansen et al., 2007; Jerevall et al., 2008; Jerevall et al., 2011; 
Kok et al., 2009; Ma et al., 2006; Ma et al., 2008; Ma et al., 2004; Sgroi et al., 2013; Wang et 
al., 2007).  This ratio is also remarkably confident when compared with the larger 21 
gene set and 81 gene signature profiles when predicting prognosis and tamoxifen 
responsiveness(Kok et al., 2009). Even more impressive is the fact that HOXB13 alone 
has been shown to be an independent predictor of tamoxifen efficacy(Jerevall et al., 
2008). Subsequent studies have confirmed these findings in breast cancer at both the 
mRNA level and  additionally in a cohort of 912 tissue microarray slides by IHC but 
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have yet to elucidate a mechanism or establish a causal role for HOXB13 in mediating 
resistance (Jerevall et al., 2010). Despite all that is known about its utility as a predictive 
marker, a causal role for HOXB13 in breast cancer pathogenesis has yet to be established. 
A potential role for this protein in cell migration was hinted at in preliminary studies 
performed in the MCF-10 breast cancer cell line but has not since been expanded upon 
in the published literature (Ma et al., 2004). 
HOXB13 is a member of the Homeobox superfamily of transcription factors that 
contain the conserved 61 amino acid DNA binding Homeodomain(Zeltser et al., 1996). 
These proteins are temporally and spatially regulated in development and play a central 
role in embryonic morphogenesis and determining position along the anterior-posterior 
axis. The 39 mammalian Hox proteins are organized into 4 genomic clusters (ABCD), 
each residing on a separate chromosome with each cluster containing 13 paralog groups. 
The DNA binding sites of these proteins have been defined by oligo arrays revealing a 
surprising lack of complexity for the specificity in binding (Berger et al., 2008). This 
implies that there may be additional factors that regulate DNA binding specificity and 
affinity or secondary DNA binding domains on the protein. In the adult, Hox proteins 
serve a role in differentiation and cell growth and their expression is tightly regulated, 
with their expression only being manifest in a tissue and cell specific manner.  However, 
their expression is frequently dysregulated in cancer (Shah and Sukumar, 2010).  Normal 
expression of HOXB13 is limited to the tail bud region including the Prostate, Colon, 
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and Urogenital Sinus but is misexpressed in a number of malignancies including that of 
breast cancer.  
The expression of HOXB13 has been shown to be regulated by several steroid 
hormones in cellular models of breast cancer.  Of note is the observation that it is 
suppressed by E2 in an ER dependent manner and that tamoxifen abrogates this 
regulation(Wang et al., 2007). The opposing role of estrogens suppressing HOXB13 and 
inducing Il17RB expression illustrates how this particular gene signature could merely 
reflect ER action and tamoxifen responsiveness. Interestingly, HOXB13 expression also 
correlates with tumor aggressiveness and closely tracks with other indicators of negative 
outcome, namely HER2 (Wang et al., 2007).  This correlation to HER2 is also noteworthy 
given the crosstalk between ER and HER2 that has previously been implicated in 
tamoxifen resistance (Shou et al., 2004). Dysregulation of estrogen signaling pathways in 
breast cancer is a well-recognized event in tumor initiation and the loss of repression on 
HOXB13 by estrogens could underlie aspects of tumorogenesis. 
This project arose as an opportunistic spinoff of an ongoing project in the 
McDonnell laboratory aimed at defining the factors expressed in prostate cancer that 
impact androgen signaling (Norris et al., 2009a).  It was the dramatic effect of HOXB13 
expression on the pharmacology of AR ligands and on AR target gene specificity that led 
us to consider that HOXB13 may play an important role in breast cancer outside of it 
being a useful marker of tamoxifen sensitivity. Specifically, in these now published 
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studies we used a microarray approach to evaluate AR target gene transcription in cells 
in which HOXB13 had been overexpressed or knocked down. In brief, we observed that 
HOXB13 can exhibit dramatic positive and negative effects on AR dependent 
transcription. In general, those genes upregulated by HOXB13 have roles in proliferation 
and those downregulated are involved in differentiation.  The determinants of such 
diverse regulation by HOXB13 are based on both promoter context and its capacity to 
work in concert with AR through a novel tethering mechanism. The ability of nuclear 
receptors to tether to promoter bound transcription factors have been previously 
reported with AP-1, NfκB, and SP1 transcription factors (Zhou et al., 2007). These 
tethering factors are thought to play a key role in priming the chromatin landscape to 
allow other signal dependent transcription factors such as nuclear receptors to activate 
particular gene expression profiles.  
In regards to therapeutic intervention, recent studies have identified cardiac 
glycosides as being able to downregulate HOXB13(Johnson et al., 2002) and this class of 
drugs may provide an alternative therapeutic opportunity for this patient population. 
While the molecular mechanisms by which HOXB13 associates with clinical 
outcome have not been defined, the aforementioned studies highlight an intriguing and 
potentially important role for it in breast cancer progression. It is therefore crucial to 
gain a better understanding of the mechanistic basis of HOXB13 to elucidate novel facets 
of resistance to ER targeted therapies, efficacy of targeting HOXB13, and to enable 
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clinicians to better-understand the value of HOXB13 expression in primary breast 
tumors. To that end, we undertook a project to evaluate the potential causal roles for 
HOXB13 on tamoxifen resistance and progression through convergence with ER 
signaling and also through alternate ER-independent mechanisms.  
3.2 Results 
3.2.1 Validation of the impact of HOXB13 on breast cancer 
progression and clinicopathological features 
As a beginning to the project, the role of HOXB13 on survival and other relevant 
clinical features was confirmed with publicly available data. For this analysis, we 
utilized individual breast cancer datasets obtained from GEO(Edgar et al., 2002) and a 
breast cancer meta-set comprising more than 5000 patients from 27 individual datasets 
as described in Chapter 4. The expression of HOXB13 was interrogated for its 
association to available clinical parameters within each dataset and across the meta-set.  
Foremost, expression of HOXB13 was not significantly different across the molecular 
subtypes, as defined by subtype-specific gene expression program. Furthermore the 
impact of HOXB13 on relapse-free survival (RFS) and distant-metastasis free survival 
(DMFS) indicated that the role of this protein in disease pathogenesis was likely to be 
complex. In confirmation of previous published data, we noted that the high expression 
of HOXB13 had a significant interaction with tamoxifen therapy failure. However, the 
effect of HOXB13 on RFS and DMFS is also markedly pronounced in the untreated state 
suggesting the interaction of HOXB13 on survival may not be tamoxifen-specific but 
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may in fact indicate a more aggressive type of tumor (Figure 3-1). The effect on survival 
was tumor subtype-specific with worse prognosis in Luminal A with a hazard ratio of 
1.37.  In contrast to the luminal tumors, HOXB13 actually associates with prolonged 
survival in basal tumors and further exemplifies the tumor-specific roles a factor can 
display within the heterogeneity of breast cancer. 
 
Figure 3-1: Clinical association of HOXB13 in a breast cancer meta-set. 
HOXB13 expression it not significantly different across PAM50 tumor subtypes (left). Kaplan-
Meier analysis of HOXB13 indicates worse prognosis in HOXB13 high tumors. Curves were 
generated within R using the survival package.  Gene expression was split into tertiles and only 
the Low (1st tertile) and High(3rd tertile) data were plotted.  Reported p-values were calculated 
using the log-rank method.   
 
The newly released breast cancer TCGA dataset contains paired samples from 
matched normal-adjacent and primary tumor biopsies. We therefore utilized this paired-
sample data to demonstrate in a case-by case manner that the expression of HOXB13 is 
specific to primary tumors when compared to expression in normal adjacent sites 
(Figure 3-2). Consequently, we proceeded to evaluate the possibility that HOXB13 was a 
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biologically relevant regulator of ER action in the breast. Similar to the meta-set, 
expression is not limited to luminal tumors as it extends across all subtypes.  
 
Figure 3-2: Waterfall Plot of HOXB13 in TCGA data. 
RNA-Seq data and clinical information from the TCGA data portal and paired-sample data was 
used for this analysis.  Data is presented as the difference in Log2 expression data from the 
primary tumor minus normal adjacent tissue in a case by case manner. Adjusted p-value is shown.  
 
 
3.2.2 HOXB13 attenuates ER signaling 
Our initial studies focused on HOXB13 as a coregulator of ER and were a logical 
extension of previous work centered on AR. To this end we used luciferase reporter 
assays to elucidate the impact of HOXB13 on ER-mediated transactivation of a synthetic 
reporter containing three tandem repeats of estrogen response elements(3x-ERE-TATA-
Luc) (Chang et al., 1999) and additionally on an endogenous promoter of PS2, 1088 base 
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pairs in length (Lu et al., 2001). For these analyses, we titrated the levels of HOXB13 
from no vector to 25ng of expression construct and found a dose-response relationship 
with either activation of 3X-ERE-TATA-Luc or repression of PS2-Luc (Figure 3-3). 
 
Figure 3-3: HOXB13 attenuates ER signaling. 
Reporter assays of HepG2 transfected cells. Cells were plated in a 96-well plate, transfected with 
luciferase reporters and relevant expression constructs, and treated for 18 hours with indicated 
treatments. Luciferase signal was normalized to beta-gal activity to control for transfection 
efficiency. 
 
3.2.3 HOXB13 promotes inflammatory pathways  
3.2.3.1 Function Coexpression Analysis identifies an interferon gene signature and 
loss of a subset of ER target genes 
Using the assembled breast cancer meta-set and TCGA data, we performed 
correlation analyses against HOXB13 in all the tumor samples and within each of the 
different PAM50 subtypes. The resulting gene list of ranked Spearman Coefficients was 
then submitted to GSEA from the Broad Institute and interrogated with gene-sets from 
the C2 and C5 databases to identify potentially meaningful biological insights of 
HOXB13 action. The enrichment analysis revealed a correlative loss of certain subsets of 
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ER target genes, but also showed a positive correlation of HOXB13 to an interferon 
signature of inflammatory genes. In particular, the CXCR3 family of chemokine ligands: 
CXCL9, CXCL10 and CXCL11 and other inflammatory genes MMP1, CCL5, and CCL18 
were tightly associated. The CXCR3 ligands are pro-inflammatory chemokines and their 
action are linked to the development of autoimmune diseases such as Graves’ disease, 
systemic lupus erythematosus, rheumatoid arthritis, and ulcerative colitis (Antonelli et 
al., 2010; Egesten et al., 2007; Lacotte et al., 2009). In breast cancer, the actions of these 
inflammatory gene products are also implicated in promoting metastases to the lung 
(Ma et al., 2009a; Ma et al., 2009b). 
A subset of ER target genes, PR, CTSD, and SCUBE2, also negatively correlated 
with HOXB13. The inverse relationship with PR is noteworthy since loss of PR, as 
proven by IHC, identifies a subclass of Luminal B patients with worse outcome and  a 
significantly decreased response to anti-estrogens (Arpino et al., 2007; Cancello et al., 
2013; Cui et al., 2005). These data may indicate that the expression programs that 
underlie resistance associated with HOXB13 are congruent with the associated 
mechanisms of resistance associated with PR loss. HOXB13 expression also strongly 
correlated with AURKA, a reliable indicator of proliferating cancer cells (Figure 3-4). 
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Figure 3-4: Association of HOXB13 with notable factors. 
A scatter density plot of HOXB13 against ER, PR and AURKA in TCGA data.  
 
 
3.2.4 HOXB13 promotes a pro-inflammatory response 
To confirm the association of HOXB13 with the inflammatory gene subsets 
identified by GSEA, MCF7 stable cell lines were engineered to constitutively express 
either control Gal4 or HOXB13 by lentivirus. Two different levels of HOXB13 expressing 
cells were made, one for very low expression equivalent to the lower third tier of 
HOXB13 expression in patients and a higher expressing cell line  Intriguingly, addition 
of HOXB13 to MCF7 cells caused growth inhibition and for a period of several weeks no 
growth was observed while control cells grew as normal. As soon as cells began to grow 
4 weeks later, the identified inflammatory targets including the CXCR3 ligands were 
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assessed by qPCR in these cells. In line with the clinical association, the genes, CXCL9, 
CXCL10 and CXCL11 were found to be dramatically upregulated relative to control cells 
(Figure 3-5).  
The CXCR3 ligands are highly expressed in type 1 macrophages. These polarized 
macrophages have an activated IRF-3 transcription program which results in interferon 
expression and subsequent STAT1/3 activation leading to CXCL9, CXCL10, and CXCL11 
upregulation. In relation to macrophages, IFN-alpha and IFN-beta were found to be 
upregulated in HOXB13 expressing MCF7 cells, and while STAT1 phosphorylation was 
not differential, STAT3 phosphorylation was increased to a minor extent. Other STAT 
genes were not assessed.   
 
Figure 3-5: HOXB13 promotes an inflammatory response. 
MCF7 stable cells were generated from Lentivirus infection of pLenti-CMV vectors containing a 
control Gal4 or HOXB13. Cells were seeded in a 6-well dish at 300k cells per well in CS-FBS 
media. Two days later cells were harvested and qPCR was used to quantify mRNA. 
 
 
3.2.5 Overexpression of HOXB13 in cellular models deregulates ER 
signaling via loss of GATA3 
 While HOXB13 may have some direct actions on ER, as observed with 
transactivation assays, the most pronounced results on ER signaling in MCF7 cells 
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expressing HOXB13 are likely attributed to loss of the pioneer factor GATA3.  GATA3 
has previously been shown to positively regulate ER levels in MCF7 cells (Eeckhoute et 
al., 2007), and indeed ER levels were decreased along with a subset of ER target genes 
(Figure 3-6). However not all genes were decreased and so as a control, SDF1 (CXCL12) 
is shown.  
 
Figure 3-6: HOXB13 expression leads to loss of ER target genes. 
qPCR results of prominent ER target genes. Cells were seeded in a 6-well dish at 300k cells per 
well in CS-FBS media. Two days later cells were treated for 18 hours with vehicle, estradiol (E2) 
or FBS media and harvested for qPCR. 
 
 
3.2.6 Loss of GATA3 promotes the HOXB13-mediated inflammatory 
phenotype.  
Beyond its role as a pioneer factor, GATA3 plays a central role in TH1 
polarization. T cell fate is determined by the interplay of two opposing transcription 
factors, GATA3 and T-bet which are activated by IFN and Il-4 respectively. Activation of 
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one pathway also feeds back and negatively inhibits the other in order to exert 
dominance and cell commitment. The GATA3 program promotes TH1 cell 
differentiation and subsequently induces chemokines CXCL9, CXCL10 and CXCL11.  In 
our system, expression of HOXB13 leads to loss of GATA3 and increases T-Bet 
expression. We hypothesized that the loss of GATA3 and associated increased Interferon 
response was mimicking the signaling paradigm manifested in T cells and that re-
expression of GATA3 could suppress the inflammatory response. Indeed, adenovirus-
induced expression of GATA3 was able to markedly decrease the majority of the 
inflammatory genes relative to control virus and rescue ER expression (Figure 3-7). 
 
Figure 3-7: Adenovirus of GATA3 ameliorates the HOXB13-induced 
inflammatory genes. 
Rescue of inflammatory genes. Cells were seeded in a 6-well dish at 300k cells per well in CS-
FBS media and infected with adenovirus at an MOI of 10. 48 hours after infection cells were 
harvested for qPCR as before. 
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3.2.7  HOXB13 induces AP-1 Responsive elements 
In the course of assessing the relationship of HOXB13 with ER it was observed 
that HOXB13 activated genes responsive to AP-1 and reporter constructs with an active 
AP-1 site, particularly the inflammatory gene MMP1 and associated luciferase reporter 
pCOL (MMP1). To verify this association with AP-1, we cloned an oligonucleotide 
containing three tandem repeats of the canonical AP-1 element, TGAGTCA upstream of 
a minimal promoter in PGL4.26.  The phorbol myristate acetate (PMA) is a known 
activator of AP-1 by mediating phosphorylation of c-Jun and c-Fos through a 
PKC/Raf/MEK dependent mechanism(Brinckerhoff et al., 1979; Sharma and Richards, 
2000).  Therefore PMA was used to induce AP-1 activity in the presence of a control, 
wild type HOXB13 and a DNA binding mutant of HOXB13 (HOXB13-3A) on these 
reporters (Figure 3-8A). These experiments revealed that HOXB13 alone induces a 
minimal AP-1 reporter to similar levels of PMA-induced activity and that this activity 
required the DNA binding domain of HOXB13.  Moreover, the transactivation by 
HOXB13 was selectively ablated with MEK1/2 inhibitors (U0126, AZD6244, PD184161) 
among a panel of inhibitors (Figure 3-8B). The association of HOXB13 and MEK are 
intriguing in regard as to how the two factors synergize. Protein levels and 
phosphorylation of MEK and ERK are unchanged after 24 and 48 hours post-
transfection of HOXB13. Furthermore, PMA-induced and HOXB13-induced activity 
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absolutely requires MEK activity, implying a dependence of HOXB13 on downstream 
effectors of MEK.  
 
Figure 3-8: HOXB13-mediated activation of AP-1 reporters is sensitive to 
MEK1/2 inhibition. 
Reporter assays of HepG2 transfected cells. Cells were plated in a 96-well plate, transfected with 
luciferase reporters and relevant expression constructs, and treated for 18 hours with indicated 
treatments. Luciferase signal was normalized to beta-gal activity to control for transfection 
efficiency. 
 
3.2.8 Cardiac Glycosides downregulate HOXB13 
The expression of HOXB13 is robustly suppressed by Ouabain and other cardiac 
glycosides, which provides a potential for therapeutic intervention of tumors with 
HOXB13. Specifically, Johnson et al., used a multiplex assay to target candidate genes in 
PC-3 prostate cancer cells with 9000 compounds and found cardiac glycosides to inhibit 
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HOXB13(Johnson et al., 2002). Cardiac glycosides are used clinically for congestive heart 
failure by inhibiting the sodium-potassium  ATPase pump and forcing intracellular 
calcium pools to increase, resulting in a stronger force of contraction by cardiac 
myocytes. Epidemiologic evidence for cardiac glycosides suggests their use is associated 
with lower mortality rates and cancer incidence (Mijatovic et al., 2007). In particular, 
Stenkvist performed a 22 year follow-up on breast cancer patients and found that 
patients taking digitalis had a 28% lower death rate (Stenkvist et al., 1982). Indeed other 
studies have also found cardiac glycosides to exhibit anti-cancer properties(Haux, 1999). 
The sodium-potassium pump is a major signaling hub and is critical for cell 
growth, differentiation and cell survival. Furthermore, it acts as a scaffold for several 
major protein interactions such as SRC, and binding of cardiac glycosides induces 
several major signal transduction pathways including the MAP kinase pathway(Haas et 
al., 2002; Li and Xie, 2009). Other signaling cascades are also activated in response to 
ionic imbalance across the membrane.  
  In order to assess if cardiac glycosides can also suppress HOXB13 in breast 
cancer cells, we used BT474 cells which have high levels of endogenous HOXB13. 
Several cardiac glycosides (Ouabain, Digoxin, Proscillaridin A, and Lanatoside C) were 
able to inhibit HOXB13 at both the mRNA and protein level following an 18 hour 
treatment (Figure 3-9). Moreover, treatment of the cardiac glycosides over a ten day 
period resulted in inhibition of growth. However, forced expression of a CMV driven 
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HOXB13 could not rescue the growth phenotype of cardiac glycosides and is somewhat 
expected given the fact that these molecules simultaneously activate so many pathways. 
 
Figure 3-9: Cardiac glycosides suppress HOXB13 in BT474 cells. 
BT474 cells were seeded in 12-well dishes at 250,000 cells per well. After 48 hours cells were 
treated with Vehicle, Ouabain, Digoxin, Proscillaradin A, or Lanatoside C at indicated 
concentrations for 18 hours (left). Western blot of protein run in parallel with qPCR assays. 
 
3.3  Discussion 
Expression of HOXB13 has been indicated to predict tamoxifen therapy outcome 
and shortened time to recurrence in patients, establishing it as a potentially useful 
biomarker. Previous studies have elucidated that HOXB13 is repressed by E2 and 
inversely correlates with ER levels in the clinic. However, the molecular mechanisms by 
which HOXB13 associates with clinical outcomes are undefined.   
In this study we identify a critical node of HOXB13 action in that it suppresses 
the expression of the pioneer factor GATA3 and leads to loss of a subset of ER target 
genes and partial loss of ER itself.  Beyond its role as a pioneer factor, GATA3 is also 
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well known to modulate inflammatory signaling and in this case, loss of GATA3 
promotes a pro-inflammatory program that relies on STAT3 phosphorylation to activate 
CXCL9, CXCL10, CXCL11, CXCL12, CCL18, CCl5, and MMP1.  Furthermore, the 
dependency on MEK1/2 and relative impact on AP-1 signaling can be explained by 
STAT3 activity. STAT3 has been previously shown to interact with AP-1 on the MMP1 
promoter by (Zugowski et al., 2011) and that binding of STAT3 was necessary for 
transcriptional regulation by AP-1. 
In the course of confirming a role for  STAT3 activation as a means to subvert the 
repressive effects of tamoxifen, Shah et al. published a report that HOXB13 induces IL-6 
and promotes STAT3 activation in a Jak-independent manner by way of mTOR (Shah et 
al., 2013). These results have not been confirmed in our studies.  
In-vitro studies have failed to show any significant resistance/desensitization to 
tamoxifen by HOXB13 when assayed by cell proliferation or soft agar assays. It is highly 
plausible that tamoxifen resistance would only be manifest in an intact environment 
allowing tumor-stromal interactions, especially since the defining characteristic of 
HOXB13 is that of promoting inflammatory genes which are involved in cell to cell 
communication signaling pathways. Future studies should therefore define the impact 
of HOXB13 on tumor growth in a syngeneic model using C57BL/6 mice with E0771 cells 
stably expressing HOXB13 or control.  
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4 Development of a breast cancer meta-set and web 
application for discovering gene function and clinical 
relationships 
4.1 Introduction 
Breast cancer is a diverse, highly heterogeneous disease with vast differences in 
outcome and response to therapeutic strategies. Gene expression profiling of tumors has 
been instrumental in defining the molecular determinants of tumor subtypes and cancer 
related genes. Wide-spread use of expression profiling of tumors have precipitated an 
abundance of gene-signatures and mixture models to assess patient survival, therapeutic 
response and identification of underlying biological processes. These top-down 
approaches are now well-established across disease states and are built around the 
paradigm of comprehensive feature analysis to aid in the diagnosis and treatment of 
cancer through data-driven discovery. With this vision, large-scale and focused studies 
have generated copious amounts of publicly available data comprising thousands of 
tumor samples. These information-rich data sets provide unprecedented opportunities 
for scientific investigation and hypothesis-driven research through bottom-up 
approaches. Leveraging this data is not without difficulties however, and requires 
programming skills and bioinformatics expertise; often discouraging effective use by 
investigators.  
The barriers to effective application of clinical data are numerous and common 
within the research setting. The process requires collection of raw data, quality checks, 
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normalization, analytical methods and visualization techniques.  Related to this process 
is the idea of generating statistically robust, reproducible results where the workflow is 
transparent and well-documented. Another point to consider is that much of the 
expression data is generated with small patient sizes and cross-validation approaches or 
data merging is necessary to elucidate the significance more broadly. Nonetheless, 
bottom-up approaches are essential in providing biologically meaningful functional 
studies to associated human tumor data.  Integration of these two distinct types of data 
is necessary to fully understand the connection of biological mechanisms and impact on 
breast cancer outcome. Therefore, an application built around an established framework 
that can perform high level analytical methods on one or a handful of genes is essential 
in empowering biologists with the tools to quickly and efficiently query data to add to 
the scientific knowledge domain.  
The focus of this study can be divided into three major points: generation of 
breast cancer meta-set to leverage the number of patient data, development of functional 
modules for high level analyses, and design of an investigator friendly user interface.  
4.2 Results 
4.2.1 Development of a breast cancer meta-set 
As breast cancer is a heterogeneous disease, large sample sizes are critical in 
generating meaningful, subtype-specific data with high confidence. While the recent 
large, multi-center effort of The Cancer Genome Atlas (TCGA) consist of ~1000 patients 
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presently, long-term clinical outcome  is yet to be realized and thus survival analysis 
requires alternative data. Early gene expression profiles relied on Affymetrix 
microarrays and these clinical data only consist of a few hundred patients per study at 
most and a few dozen on the low end. Thus it is necessary to cross-validate results 
across many studies or to perform a meta-analysis to infer significance. For this purpose, 
data sets are often pooled to increase sample size to extend results obtained from single 
studies. However, combining data in this manner, especially in breast cancer, poses a 
number of statistical difficulties and often results in gross errors.  These challenges arise 
from the fact that studies are often performed on different platforms by different 
facilities with different methods of tumor extraction protocols. Moreover, clinical 
cohorts in these studies are often divergent on ethnicity, tumor subtype, and other 
patient characteristics central to the associated trial.  Thus, non-biological experimental 
variations or “batch effects” are often hard to account for while conserving true 
biological relationships. Consequently, a simple merging of data sets is unadvised. For 
this purpose, normalization procedures which allow for gene-wise linear pairing and 
cross-platform methodologies have been developed (Benito et al., 2004; McCall et al., 
2010; Shabalin et al., 2008).  In particular, frozen Robust Multi-array (fRMA)(McCall et 
al., 2010) is a normalization procedure similar to RMA that parameterizes the signal for a 
given platform using “frozen vectors” and normalizes the data such that each array can 
 83 
be processed independently while still yielding consistent results when data is from 
different sources.  
In order to collect as many data sets as possible, the gene expression omnibus 
(GEO) was queried for breast cancer datasets that were performed on HGU133A or 
HGU133Plus2 Affymetrix platforms. In total, 25 non-redundant data sets were identified 
comprising 4885 patients. Datasets used: GSE10780, GSE11121, GSE12093,GSE12276, 
GSE1456, GSE16391, GSE16446, GSE17705, GSE17907, GSE19615, GSE20194, GSE2034, 
GSE20685, GSE20711, GSE2109, GSE21653, GSE22093, GSE24185, GSE25066, GSE3494, 
GSE5460, GSE6532, GSE6532, GSE7390, and GSE9195.  The raw data was downloaded 
from GEO, and each dataset was normalized with fRMA to remove platform-specific 
batch effects. Note that the two Affymetrix platforms are not directly comparable using 
fRMA and further data merging techniques are required. Therefore, the data was then 
combined using the COMBAT algorithm implemented in the sva package within R 
(Leek et al., 2012) with a design matrix to account for known covariates including data 
source and platform. Each tumor was then classified into PAM50 (Parker et al., 2009) 
molecular subtypes using genefu (Haibe-Kains et al., 2012). To confirm normalization, a 
Multi-dimensional Scaling (MDS) plot was used to visually inspect the data in relation 
to platform and tumor subtype (Figure 4-1). It is clear that the data prior to merging is 
grouped relative to platform, while after merging is grouped strongly with tumor 
subtype.  
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Figure 4-1: MDS plot of data before and after merging. 
MDS plot of 500 random patient data before adjustment (left) and after COMBAT adjustment 
(right). Tumor subtypes and Affymetrix platform are represented by color and shape respectively. 
Both plots are on the same scale.  
 
Additionally, ER levels were assessed to ensure that a bimodal distribution was 
present after merging the data with COMBAT (Figure 4-2A). Notably, when the data is 
plotted according to its originating data source (Figure 4-2B), the histogram in red is 
situated between the two bimodal distributions. However, this data set (GSE10780) is 
comprised of histologically normal tissue and profiles accordingly.  
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Figure 4-2: Histogram of ER expression. 
Density distribution plot of ER expression levels of probe 205225_at. Density fitting curve for 
bimodal distribution was also calculated with the R package mixtools.  
 
Another formidable task in data set merging is in aggregating the associated 
clinical data, especially in light of the fact that there is not a standard format of 
annotation used in the studies. Data from GEO, published reports, author’s websites, 
and additionally by means of communication, was collected and manually curated. In 
this manner, patient characteristics including age, node involvement, neo-adjuvant 
treatment, adjuvant treatment, survival end points and other relevant data was 
obtained.  
After merging gene expression data with clinical information, it was apparent 
that some patients were represented in multiple studies and therefore these duplicates 
were removed to form a database of non-redundant patient samples. Furthermore, some 
arrays failed to pass quality checks and were also removed.  
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4.2.2 Development of functional modules 
One of the key aims of this project was to develop a set of functions that allow 
rapid generation of data with minimal input to address key questions. Establishment of 
routine procedures leads to reproducible results and instills confidence to others about 
the integrity of the data being generated. Other problems related to use of clinical 
expression data is the fact that one-off data sets misrepresent the underlying biology and 
meta-analytical procedures are necessary to confirm data concordance. In this regard, 
metrics were instituted into the analytical functions to report dataset-specific results.  
Two independent data sources are used by the functions. The aforementioned 
breast cancer meta-set is used in all functions while TCGA data is used for everything 
except survival analysis. These data are stored in a SQLite database format for rapid 
retrieval of the data of interest. Also, the R environment is used for data retrieval, 
processing and graphing. Three different algorithms to determine tumor subtype are 
incorporated: PAM50 (Parker et al., 2009), MOD1, and MOD2 (Desmedt et al., 2008; 
Wirapati et al., 2008). Functions developed include survival analysis of a single factor, 
survival analysis of a gene-set, expression of a single factor, expression of multiple, and 
correlation analysis with subsequent pathway enrichment. Each set of functions are 
described below with representative output. All code is available at 
(https://github.com/jasper1918/GeneAnalytics). 
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These functions require input of a gene identifier and can be queried either with 
an Affymetrix probe set, (e.g. 2055225_at), or with a gene symbol, (e.g. ESR1). In the 
latter method, gene symbol are mapped to associated Affymetrix probe sets and this 
often results in multiple matching probe sets. In the case of multiple matching probe 
sets, typically probe set intensities are averaged or the most invariant probe set used, but 
this can lead to unreliable results. To illustrate the point, nine probe sets for ER are 
represented on the HGU133A platform and only one, 205225_at, has been shown to 
correlate with ER status by IHC. To this end, a series of metrics related to gene-
specificity of the probe, transcript coverage, and robustness can be used to identify the 
highest scoring probe set as previously published (Li et al., 2011).  
4.2.2.1 Expression Analysis 
The identification of tumor subtypes is based on the relative differences of a 
subset of genes across tumors. Thus, profiling a single factor or handful of genes across 
tumor subtypes can be used to inform biological functionality or to identify which 
tumors are more likely to respond to therapeutics targeting the factor of interest. Two 
functions are available for expression analysis: single gene expression and a heatmap for 
visualizing multiple genes. Parameters available to the user include gene identifier and 
choice of subtype algorithm.  
Genes from GO term 0046605 representing ‘regulation of centrosome cycle’ were 
used as input for expression analysis in a demonstrative example below (Figure 4-3A). 
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Both Aurora Kinase A (AURKA) and NIMA-related kinase 2 (NEK2) show strong 
differential expression across the subtypes in these results. The kinase, AURKA is 
involved several steps of mitosis and has been implicated in disease progression and 
tumor aggressiveness in breast cancer (Fu et al., 2007). Further analysis of AURKA 
expression reveals that it is highly expressed in Basal-like HER2-enriched, and Luminal 
B tumors, but is much less represented in Luminal A and Normal-like tumors (Figure 4-
3B). 
 
Figure 4-3: Expression Analysis of AURKA. 
Plots produced from the breast cancer meta-set using the expression heatmap function with GO 
term 0046605 (A), and single gene expression of AURKA across PAM50 subtypes (B).  
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4.2.2.2 Survival analysis 
Kaplan-Meir curves are used to assess the impact of a gene or gene-set on 
survival. In this approach relapse-free survival and distant metastasis-free survival data 
from the breast cancer meta-set are used in conjunction with censor information to build 
a cox proportional hazard model using the surv package in R. Parameters available to 
the user include gene identifier, months to plot, choice of tumor subtype algorithm, 
method of splitting low and high groups, whether to include tamoxifen or 
chemotherapy treated patients, and relevant survival end point. Log-rank p-values are 
reported on all plots. Concordance-Index (c-index) scores (Schröder et al., 2011) are also 
generated for each data set in order to report on the relative impact of each study on 
survival outcomes for each subtype.  
Survival analysis can be run with either a single gene or with multiple genes to 
form a gene-set. With a gene-set, signature scores are calculated for each patient and 
subsequently split into low and high groups for plotting. Continuing with the example 
set of genes from go term 0046605, survival curves of the signature scores are profiled 
across all tumor subtypes using the combination of RFS and DMFS endpoints (Figure 4-
4). Furthermore, to address data consistency a plot of the c-index scores of each dataset 
is produced for each tumor subtype. The Luminal B plot of c-index scores is shown in 
Figure 4-4D.  
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Figure 4-4: Survival analysis of G0:0046605 genes. 
Plots produced from the breast cancer meta-set using the gene-set survival function. Kaplan-
Meier curves are generated for all tumors (A), Luminal B tumors (B) and Basal-like tumors (C). 
Plot of the Concordance-Index scores for each data set used. Gene expression was split on the 
median into low and high classifications and Kaplan-Meier curves were plotted in R.   
 
In a similar manner, AURKA is profiled across all tumors and subtypes using the 
combination of RFS and DMFS as an end point (Figure 4-5). Data from the breast cancer 
meta-set reveals that while it is expressed in high levels across both ER negative and ER 
positive subtypes, a negative association of the gene-set or AURKA on prognosis is only 
relevant to ER positive groups (not all data shown). The plot of c-index scores for 
Luminal B reveals that 13 of the 15 datasets used to generate the merged survival curve 
for AURKA are trending together while two show opposing effects.  
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Figure 4-5: Survival analysis of AURKA. 
Plots produced from the breast cancer meta-set using the single gene survival function. Kaplan-
Meier curves are generated for all tumors (A), Luminal B tumors (B) and Basal-like tumors (C). 
Plot of Concordance-Index scores for each data set used. Gene expression was split on the median 
into low and high classifications and Kaplan-Meier curves were plotted in R.   
 
4.2.2.3 Forest plot 
The results above suggest that genes represented in the example using GO term 
0046605 representing ‘regulation of centrosome cycle’ are highly correlated with tumor 
progression in Luminal B tumors. While AURKA profiles very similar to the gene set 
overall, a separate function can be used to assess the effect of each gene within a gene set 
on survival. The forest plot function requires the same set of parameters from the gene-
set survival. Results with GO term 0046605 reveal that AURKA is indeed highly 
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associated with a negative outcome among the gene-set along with NEK and CENPJ 
genes. 
 
Figure 4-6: Forest plot of GO:0046605 genes. 
Plots produced from the breast cancer meta-set using the forest plot function for genes in GO 
term 0046605.  
 
4.2.2.4 Functional co-expression analysis 
With several thousand samples of patient derived expression data it is possible 
to utilize a systems biology approach to infer biological insight and functionality of a 
gene from a co-expression network and topology approaches. These discovery 
approaches also hold the potential in identifying co-regulatory gene-networks, 
transcription factor programs, and nodes of convergence for pathways that cross-talk. 
Gene co-expression networks have been used previously to elucidate intersecting genes 
to build prognostic signatures, identify transcriptional networks, and discover gene 
complementarity (Carter et al., 2004; Ruan et al., 2010; Xiang et al., 2012; Zhang and 
Horvath, 2005). 
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This function takes a gene-centric approach to build a co-expression network 
utilizing Spearman’s rank correlation coefficients of a single gene of interest with every 
other gene represented in the data set. This is done across all tumors and additionally in 
each tumor subtype. Thus, the only two parameters necessary are a gene identifier and 
choice of a tumor subtype algorithm.   
A table of correlation coefficients is returned for each tumor subtype and across 
all tumor datasets. The function then takes the top 50 genes that highly correlate and the 
bottom 50 that negatively correlate with the factor of interest to build a correlation 
network of all gene pairs and produces plots of correlation matrices as corelograms and 
node-edge graphs. Furthermore, the resultant rank list of correlation coefficients is used 
as input for pathway enrichment procedures using GSEA, GAGE, and against 
individual databases of pathways including KEGG and Reactome. Each of these 
approaches produces a table and figure of the most significantly associated 
relationships.  
As a proof of concept, AURKA was used as input for Functional co-expression 
analysis. GSEA results of the C2 database (Table 4-1) identified the AURKA ranked 
correlation list to be relatively enriched in gene-sets central to cancer progression, 
mitosis, and proliferation; strongly coinciding with its described role from the published 
literature. Other pathway approaches also strongly indicated a role for AURKA in 
mitosis, proliferation, cell cycle, and cancer-specific pathologies. 
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Table 4-1: GSEA results from Functional co-expression analysis for AURKA. 
Gene Set Name p.geomean stat.mean p.val q.val set.size exp1 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 3.20E-89 22.95752 3.20E-89 1.33E-85 446 3.20E-89 
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP 2.51E-44 19.19713 2.51E-44 2.08E-41 147 2.51E-44 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 1.06E-41 18.36404 1.06E-41 7.33E-39 140 1.06E-41 
TARTE_PLASMA_CELL_VS_PLASMABLAST_DN 6.38E-40 14.2299 6.38E-40 3.79E-37 300 6.38E-40 
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP 6.40E-38 13.44016 6.40E-38 3.33E-35 445 6.40E-38 
REACTOME_CELL_CYCLE 8.43E-38 13.63092 8.43E-38 3.90E-35 342 8.43E-38 
KOBAYASHI_EGFR_SIGNALING_24HR_DN 1.11E-37 13.93454 1.11E-37 4.60E-35 247 1.11E-37 
BERENJENO_TRANSFORMED_BY_RHOA_UP 1.77E-36 13.09974 1.77E-36 6.68E-34 479 1.77E-36 
GARY_CD5_TARGETS_DN 2.31E-36 13.28923 2.31E-36 7.99E-34 362 2.31E-36 
REACTOME_CELL_CYCLE_MITOTIC 2.27E-35 13.28379 2.27E-35 7.27E-33 281 2.27E-35 
BENPORATH_PROLIFERATION 8.67E-35 15.11737 8.67E-35 2.58E-32 131 8.67E-35 
BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP 3.93E-34 13.67147 3.93E-34 1.09E-31 185 3.93E-34 
LINDGREN_BLADDER_CANCER_CLUSTER_3_UP 5.11E-34 12.98491 5.11E-34 1.33E-31 275 5.11E-34 
ZHANG_TLX_TARGETS_60HR_DN 1.07E-33 13.09477 1.07E-33 2.62E-31 230 1.07E-33 
REACTOME_DNA_REPLICATION 2.37E-33 13.58798 2.37E-33 5.47E-31 173 2.37E-33 
 
All correlation matrices and pathway enrichment results are conveniently 
compressed into a single file for download and provide further opportunities to leverage 
the data for subtype-specific analysis, differential correlation networks, and cluster-
specific approaches.  
4.2.3 Web application  
In order to make the aforementioned breast cancer meta-set and associated 
functions accessible and easy to use, a web-based interface was developed. The web 
application, named GeneAnalytics, is built on HTML with ajax and PHP helper 
functions to auto-fill gene identifiers and map gene symbols to probe set identifiers for 
quick input. Each function is associated with an individual web form that when 
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submitted, calls a Perl script via a Common Gateway Interface (CGI) to extract user 
parameters and prepare necessary file requirements. Perl then calls an R script to 
assemble necessary data, run the described analysis and generate the appropriate files 
and figures. All results are then presented back to the user with a link to download the 
files for permanent record keeping. It is also important to note that all figures are 
generated in PDF format to maintain high quality, high resolution images which can be 
adapted for publication. On average, each process takes about 10 seconds to run with 
exception to the functional co-expression analysis, which takes closer to a minute to 
finish. A sample screen shot can be seen in Figure 4-7. 
 
Figure 4-7: Screen shot of GeneAnalytics website. 
 
A screen shot of the single gene survival function made available at GeneAnalytics.  
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4.3 Discussion 
The present study makes use of the publicly available datasets to generate an 
integrative database of 4885 patients from 25 independent studies. Furthermore, 
analytical methods and functions were developed to efficiently use and apply the data. 
Access to the breast cancer meta-set and functions are made available to end users via a 
web interface.  
 Clinical data sets are abundant and their use in in discovery and validation 
contexts is well documented (Chang et al., 2011; Haibe-Kains et al., 2012; Magnani et al., 
2011; Parker et al., 2009; Perou et al., 2000; Shi et al., 2010; Xiang et al., 2012). 
Nonetheless, use of gene expression data for these purposes remains a challenging task 
within the broad scientific community due to lack of bioinformatics training and the fact 
that no established frameworks exist. While researches can access gene expression 
relative to clinical features in websites such as Oncomine (Rhodes et al., 2007), several 
limitations exist. The GeneAnalytics web application is the first to offer access to a breast 
cancer meta-set and offer high level analytical functions to apply the data in a 
meaningful way to the research setting.  
 In summary, the breast cancer meta-set and associated access through the 
GeneAnalytics web sites provides novel opportunities for researchers to integrate 
functional studies with tumor derived expression data to further our understanding of 
cancer related processes. 
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5 Conclusions and future directions 
Despite initial success, resistance to both anti-estrogens and aromatase inhibitors 
is common, and these tumors continue to express ER. Furthermore, there is abundant 
evidence that ER transcriptional activity drives cell growth in endocrine resistance in the 
clinic.  Likewise, the growth of TamR xenografts is blunted by ICI and the anti-estrogen 
bazedoxifene. The ER signaling program is plastic and can be reprogrammed in a 
cellular context by chromatin accessibility, epigenetics, coregulators and other 
transcriptional initiators including pioneer factors. The results of these studies have 
identified several transcription programs that are important to the development of 
tamoxifen resistance in breast cancer. In particular, FOXA1 binding is enriched in 
differentially sensitive DNase regions in the TamR model where it drives expression of 
key target genes whose actions are well-known in the pathogenesis of breast cancer. 
The FOXA1 transcriptional program is related to ER signaling in that 
approximately 50% of its binding sites overlap with ER binding events. The increased 
role of FOXA1 in mediating the actions of ER is prominent in the TamR cell model and 
underlies resistance by establishing competent binding sites that allow ER to bind to 
novel regions and also to facilitate ER to engage chromatin in the absence of ligand at 
levels similar to ligand-induced activation. This phenomenon known as ligand-
independent activation may require other upstream signaling mechanisms to modify 
ER, but the relevance of these studies is that FOXA1 obviates the need for ligands to 
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promote interactions of ER with coregulators to modify the chromatin environment. 
Efforts to understand the mechanism by which tumors adapt to  SERDs, or AIs is an area 
that requires further discovery to understand the context to which they overlap or are 
divergent. From which, the FOXA1 adaptive program that promotes resistance may be 
better suited to a particular, SERM, SERD or AI. However we do have limited evidence 
that AIs would lead to a similar program from analysis of long-term estrogen deprived 
MCF7 cells that adopt a similar expression program as TamR cells. Future studies are 
necessary to identify whether FOXA1 alone is sufficient to support basal activities of ER, 
whether ER coregulators are necessary and to what extent other ER-directed therapies 
can inhibit ER at these FOXA1-dependent loci.  
Our results also reveal a functional difference of FOXA1 activity in TamR cells 
compared to MCF7 cells and suggests that FOXA1 may be modified to co-opt a growth 
program. One potential means of increased activation may rest on the ability of FOXA1 
to respond to upstream signaling cascades. Phosphorylation mapping of FOXA1 
revealed a loss of phosphorylation at S331 in TamR cells and functionality of this site is 
currently being tested. In addition, our sequencing results identified the variant S448N, 
rs33984772, at a low frequency (~10%) in MCF7 cells, but TamR cells carry the variant 
allele at a higher frequency (~58%); suggestive of biological functionality of S448. 
Another report identified FOXA1 to be acetylated by P300 and consequently diminishes 
DNA binding, an event which may be due to growth factor signaling (Katika et al., 
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2013). Mutational studies of FOXA1 are ongoing to determine the functionality of these 
identified sites and the relevance to which they promote FOXA1 binding, stabilization 
and enhanced transcriptional activity.  
There are many aspects of ER signaling and cross-regulatory actions of FOXA1 
signaling program that remain to be fully elucidated.  Although there has been success 
with anti-estrogens, an emerging paradigm in oncology field is focused on targeting co-
dependent pathways to sustain inhibition of adaptive mechanisms that take over to 
reactivate a transcriptional program.  In the context of breast cancer, a better 
understanding of the convergent pathways and adaptive mechanisms that allow ER to 
escape tamoxifen-mediated inhibition to maintain a central role in driving tumor growth 
is necessary. Targeting FOXA1 directly may prove beneficial in this regard but there is 
also a potential downside in that long term therapy may promote tumors to adopt an ER 
negative basal-like expression program, a tumor subtype that has unfavorable outcomes. 
Thus, inhibitors of kinases or key nodes of pathways upstream of FOXA1 may be useful.  
However, it is currently unclear what pathways and signaling cascades are necessary to 
mediate this switch. Therefore, screening platforms using small ligands, kinase 
inhibitors, or shRNA libraries may be able to identify these convergent pathways.  The 
TamR model is perfectly suited for this case as it is the first observation of heightened 
FOXA1 activity in a model of resistance and allows for a differential screen of the TamR 
model compared to MCF7 cells to separate the negative and positive aspects of FOXA1. 
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For this purpose gene expression of TamR-specific FOXA1 regulated genes can be used 
as a measured outcome and end point in determining therapeutic utility.  
The mass-spec results have revealed ~100 factors that preferentially bind in 
TamR cells. These factors further represent novel drug candidates to delay the FOXA1-
dependent resistant mechanism. However, confirmation of these interactions in the 
context of cell signaling is necessary, and it will be important to ascertain their role in 
pathologies associated with ER and FOXA1.  
Taken together, these studies advance our understanding of both ER and the 
adaptive mechanisms that promote resistance to anti-estrogens. This work has identified 
a novel role for FOXA1 in driving tamoxifen resistance by means of reactivation of ER 
pathways and ER-independent gene expression.  Experimental evidence indicates an 
altered usage of FOXA1 localization, modification and DNA occupancy in a tamoxifen 
resistant model. Additional studies will be necessary to elucidate the positive and 
negative impacts of FOXA1 on biological processes and whether a FOXA1 therapeutic 
may be used to delay recurrence. A further understanding of the role of FOXA1 in 
progression to and maintenance of tamoxifen resistance will determine whether this 
essential factor can be effectively targeted to delay tumor progression and improve the 
efficacy of ER-targeted therapies. 
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6 Materials and Methods 
6.1 Chemicals  
ER ligands obtained from Sigma (St. Louis, MO) include: 17b-Estradiol [50-28-2] 
(E8875), Fulvestrant (ICI) [129453-61-8] (I4409), and 4-hydroxytamoxifen [68047-06-3] 
(H7904). Cardiac glycosides used were also purchased from Sigma: Digoxin [20830-75-5]  
(D6003),Ouabain, [11018-89-6] (O3125),Lanatoside C [17575-22-3] (L2261), and 
Proscillaradin A [466-06-8] (P2428).Other inhibitors used include: AZD6244 [606143-52-
6] from Selleckchem, U0126 [109511-58-2] from Sigma (U12), PD184161 [212631-67-9] 
from Cayman, LY294002 [934389-88-5]  from Sigma (L908), and Farnesylthiosalicylic 
acid (FTS) [1092521-74-8] from SCBT (sc-223986). PCR and qPCR reagents were 
purchased from Bio-Rad (Hercules, CA), Qiagen (Valencia, CA), Integrated DNA 
Technologies (Coralville, IA), and Sigma.  
6.2 Antibodies 
The following antibodies were purchased from Santa Cruz Biotechnology: 
HOXB13 antibody (H-80): sc-66923, HOXB13 antibody (F-9): sc-28333, and FOXA1 
antibody (C-20): sc-6553. Remaining antibodies were purchased from Abcam: FOXA1 
antibody (ab23738), FOXA2 antibody (ab60721), STAT1 antibody (ab2415), STAT1 
(phospho Y701) [M135] antibody (ab29045), STAT3 (phospho Y705) antibody [EP2147Y] 
(ab76315). 
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6.3 Plasmids 
Expression plasmids for HOXB13 were previously generated in the lab (Norris et 
al., 2009b). Reporter construct for PS2-Luc (Lu et al., 2001), and the 3XERE-TATA-Luc 
(Hall and McDonnell, 1999) have been described previously. Luciferase reporters for 
pCOL (MMP1) were generated from constructs described elsewhere (Fan et al., 1996) 
and made as follows: pCOL-FL (F-atcgctcgagGAAGAGCCACCGTAAA,  R-
cgataagcttGCCTTTGTCTTCTTTC ), pCOL-1:292 (F-
atcgctcgagGAAGAGCCACCGTAAA, R-cgataagctttcaaacaagatgtgtg), pCOL-292:380 (F-
atcgctcgagaagttaatcatgacat, R-cgataagcttgctatgaatagactag), pCOL-380:452 (F-
atcgctcgagtaatcaagaggatgtt R-cgataagcttatatatagagtccttg), and pCOL-452:538 (F-
atcgctcgagacagagggagcttcct, R-cgataagcttGCCTTTGTCTTCTTTC). The 3x AP-1 reporter 
was cloned with the insert tcgagGTTGAGTCACGGTTGAGTCACGGTTGAGTCACGa. 
FOXA1 was cloned into pLenti_Puro using an ORF obtained from Open Biosystems, 
clone id:52698380. FOXA2 was also cloned into Plenti_Puro using a clone from PlasmID 
Database at Harvard, clone id: HsCD00044936.  
6.4 Cell Culture 
The MCF7, MARCO and TamR cell lines were maintained in Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12). TamR cells were also kept 
under constant selection with 100nM 4-OHT.  BT474 Cells were grown in RPMI 1640. 
HEPG2 cells and BT483 cells were grown in DMEM. All cell lines were supplemented 
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with 8% fetal bovine serum (FBS) or charcoal stripped FBS (CS-FBS) (Hyclone 
Laboratories, Logan, UT), 0.1 mM non-essential amino acids (NEAA) and 1 mM sodium 
pyruvate (NaPyr).  
6.5 RNA Isolation and qPCR 
Cells were seeded in 6-well plates in phenol red-free media containing 8% CS-
FBS for 48 hours and treated with ligands as indicated. After the indicated time period, 
cells were harvested and total RNA was isolated using the AurumTM Total RNA Mini Kit 
(Bio-Rad, Hercules, CA). One microgram of purified RNA was reverse transcribed using 
the iScript cDNA synthesis kit (Bio-Rad). The Bio-Rad CFX384 Touch Realtime PCR 
Detection System was used to amplify and quantitate levels of target gene cDNA.  
Reactions for qPCR were performed with 1 µL cDNA, 10 µM specific primers, and iQ 
SYBRGreen supermix (Bio-Rad). Data are normalized to RPLP0 (36B4) housekeeping 
gene and presented as fold expression relative to controls. Data is presented as the mean 
± SEM for triplicate amplification reactions from one representative experiment. Unless 
otherwise indicated, experiments were performed at least three independent times with 
coincident results. Human qPCR primer sequences are listed in Table 6-1. 
 
Table 6-1: qPCR primers used. 
Identifier Symbol Primer Sequence 
NM_005409 CXCL11 CXCL11-F ACTCCTTCC AAGAAGAGCAGCA 
NM_005409 CXCL11 CXCL11-R CCATGCCCTTCACACTCATGTT 
NM_002416 CXCL9 CXCL9-F GTAGTGAGAAAGGGTCGCTGT 
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NM_002416 CXCL9 CXCL9-R AGGGCTTGGGGCAAATTGTT 
NM_001565 CXCL10 CXCL10-F GTGGCATTCAAGGAGTACCTC 
NM_001565 CXCL10 CXCL10-R TGATGGCCTTCGATTCTGGATT 
NM_001504 CXCR3A CXCR3A-F ACCCAGCAGCCAGAGCACC 
NM_001504 CXCR3A CXCR3A-R TCATAGGAAGAGCTGAAGTTCTCCA 
NM_001142797 CXCR3B CXCR3B-F TGCCAGGCCTTTACACAGC 
NM_001142797 CXCR3B CXCR3B-R TCGGCGTCATTTAGCACTTG 
NM_002988 CCL18 CCL18-F CTCCTTGTCCTCGTCTGCAC 
NM_002988 CCL18 CCL18-R TCAGGCATTCAGCTTCAGGT 
NM_024013 IFNA2 IFNA2-F CAGAGTCACCCATCTCAGCA 
NM_024013 IFNA2 IFNA2-R CACCACCAGGACCATCAGTA 
NM_000619 IFNG IFNG-F TCAGCTCTGCATCGTTTTGG 
NM_000619 IFNG IFNG-R GTTCCATTATCCGCTACATCTGAA 
NM_002051 GATA3 GATA3-F GCGGGCTCTATCACAAAATGA 
NM_002051 GATA3 GATA3-R GCTCTCCTGGCTGCAGACAGC 
NM_006361 HOXB13 HOXB13-F GTGCTGCCCGCTGGAGTC 
NM_006361 HOXB13 HOXB13-R AGTTACCTGGACGTGTCTGTGG 
NM_001145938 MMP1 MMP1-F GGTCTCTGAGGGTCAAGCAG 
NM_001145938 MMP1 MMP1-R CCAGGTCCATCAAAAGGAGA 
NM_004217 AURKB AURKB_480 ATCAGCTGCGCAGAGAGATC 
NM_004217 AURKB AURKB_629 AGCTCTTCTGCAGCTCCTTG 
NM_003225 TFF1 TFF1_41 TGGCCACCATGGAGAACAAG 
NM_003225 TFF1 TFF1_180 CGTGACACCAGGAAAACCAC 
NM_016095 GINS2 GINS2_460 CCAAACTCCGAGTGTCTGCT 
NM_016095 GINS2 GINS2_588 TGTACATGTGGTTGAGCGCT 
NM_012259 HEY2 HEY2_499 TCAGGCAACAGGGGGTAAAG 
NM_012259 HEY2 HEY2_593 GCGCAACTTCTGTTAGGCAC 
NM_012391 SPDEF SPDEF_1079 AAAGAGCGGACTTCACCTGG 
NM_012391 SPDEF SPDEF_1201 CTTGAGGAACTGCCACAGGT 
NM_153321 PMP22 PMP22_279 CGCAACTGATCTCTGGCAGA 
NM_153321 PMP22 PMP22_395 ATCGACAGGATCATGGTGGC 
NM_004316 ASCL1 ASCL1_1151 CCCCCAACTACTCCAACGAC 
NM_004316 ASCL1 ASCL1_1267 TGAAGTCGAGAAGCTCCTGC 
NM_002275 KRT15 KRT15_830 CGAGTCCTGGATGAGCTGAC 
NM_002275 KRT15 KRT15_952 CTGGCTGCTGAACTCCTTCA 
NM_021810 CDH26 CDH26_434 CCAGATGCCACAATGCACAG 
NM_021810 CDH26 CDH26_570 CCTTCCTCGCTGTAGACGTG 
NM_181803 UBE2C UBE2C_246 CGAGCTCTGGAAAAACCCCA 
NM_181803 UBE2C UBE2C_360 AAGACGACACAAGGACAGGC 
NM_004316 ASCL1 ASCL1_1563 GAGCAACTGGGACCTGAGTC 
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NM_004316 ASCL1 ASCL1_1685 TCAGCTGTGCGTGTTAGAGG 
NM_024915 GRHL2 GRHL2_496 GTGATGAGGACAGTGCTGCT 
NM_024915 GRHL2 GRHL2_596 TTGGCTGTCACTTGCTTTGC 
NM_001032280 TFAP2A TFAP2A_1724 ACCGACAACATTCCGATCCC 
NM_001032280 TFAP2A TFAP2A_1815 CAGCAGGTCGGTGAACTCTT 
NM_003221 TFAP2B TFAP2B_174 ACCTCCTAGAGACCAGGCTG 
NM_003221 TFAP2B TFAP2B_323 CTCGAGTAGGGTCCTTGGGA 
NM_003222 TFAP2C TFAP2C_993 CTGTCCCCACCTGAATGCTT 
NM_003222 TFAP2C TFAP2C_1095 TCTTGTCCAACTTCTCCCGC 
uc010tpz.2 FOXA1_1 FoxA1_Iso1_125 AAAACGCGTATTGGAACTGC 
uc010tpz.2 FOXA1_1 FoxA1_Iso1_226 GCCTGAGTTCATGTTGCTGA 
uc001wuf.3 FoxA1_2 FoxA1_Iso2_327 GAAGATGGAAGGGCATGAAA 
uc001wuf.3 FoxA1_2 FoxA1_Iso2_423 GCCTGAGTTCATGTTGCTGA 
 
6.6 Transient Transfection Assays 
For reporter gene assays, cells were seeded in 96-well plates in phenol red-free 
MEM containing 8% charcoal-stripped fetal bovine serum (CS-FBS) (Hyclone, Logan, 
UT), 0.1 mM NEAA and 1 mM NaPyr 24 h before transfection. DNA was introduced 
into the cells using Lipofectin (Invitrogen) or Fugene 6 (Promega) -mediated transfection 
as described by the manufacturer. Briefly, triplicate transfections were performed using 
500ng of total DNA; within each experiment, the total amount of DNA used to transfect 
each plate was kept constant by addition of the corresponding empty expression vector 
DNA lacking a cDNA insert. Cells were incubated with the DNA-transfection mixture 
for 24 h. Next, the transfection mix was replaced with fresh media containing the 
appropriate ligands. Following overnight treatment, luciferase and β-galactosidase (β-
gal) activities were assayed on a Fusion Alpha-FP HT Universal Microplate Reader 
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(Perkin Elmer, Danvers Grove, IL). Results are expressed as relative luciferase activity 
(normalized to β-gal for transfection efficiency) for one representative experiment 
performed in triplicate, and error bars indicate the standard error of the mean (SEM) for 
the triplicate wells. 
6.7 Viral Stable Cell Generation 
Adenoviruses expressing ß-gal, ER and GATA3 were generated using the 
ViraPower Adenoviral Expression System (Invitrogen) and were amplified and purified 
by CsCl2 centrifugation.  
For retrovirus generation, 293TS cells were plated at 2E6 in a10cm dish in DMEM 
8% FBS. The next day 8ug of target vector, 8ug of PCL10A1 was mixed with 600 ul 
OPTI-MEM for 5 minutes and 36 ul of Fugene 6 was added to the tube. After 30 minutes, 
transfection mix was added dropwise to the cells using a 1ml pipette. The following day, 
media was replaced with DMEM containing 2mM caffeine.  72 hours after transfection, 
virus was harvested by filtration through a .45uM filter and polybrene was added at 
8ug/ml prior to infecting target cells. MCF7 cells were selected at 1ug/ml of Puromycin 
and BT474 cells were selected at .5ug/ml.  
Lentiviral constructs were made from PLenti_Puro (Campeau et al., 2009) and 
transcript cDNA was cloned using LR Clonase II. For viral generation, 293FT cells were 
plated at 3E6 in a10cm dish in DMEM 8% FBS. The next day 6ug of target vector, 4.5ug 
of dr8.2 dVPR, and 1.5ug VSVG was mixed with 600ul OPTI-MEM for 5 minutes and 
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36ul of Fugene 6 was added to the tube. After 30 minutes, transfection mix was added 
dropwise to the cells using a 1ml pipette. The following day, media was replaced with 
DMEM containing 2mM caffeine.  72 hours after transfection, virus was harvested by 
filtration through a .45uM filter and polybrene was added at 8ug/ml prior to infecting 
target cells. MCF7 cells were selected at 1ug/ml of Puromycin and BT474 cells were 
selected at .5ug/ml.  
6.8 RNA-Seq 
Two independent biological replicates for each cell line treated with Vehicle or 4-
OHT were harvested as described above for RNA. Libraries were generated using 
Illumina TruSeq Stranded mRNA kit according to manufacturer protocols. Libraries 
were submitted to 100bp PE sequencing on Illumina HiSeq. FASTQ files were pre-
processed to remove adapters, and low-quality 3’ reads and aligned to the hg19 genome. 
Resulting BAM files were filtered to remove multi-mapped reads and rRNA reads. 
Reads were quantified using easyRNASeq (Delhomme et al., 2012) over 
ensemble transcripts in R and genes with more than 2cpm in at least two conditions 
were brought forward to edgeR(Robinson et al., 2010) for differential expression. A 
multi-factorial design was incorporated to account for resistance and sensitive cells in 
each treatment state. TMM normalization was used and genes with p<.01 were 
considered differentially expressed for subsequent analyses. 
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Pathway analyses was accomplished with GAGE(Luo et al., 2009) and 
GSEA(Subramanian et al., 2005). GSEA results were further processed using the 
“Enrichment Map” plugin. 
6.9 siRNA Experiments 
For experiments involving transient transfection of small interfering RNA 
(siRNA), validated Stealth siRNA or siRNA control were obtained from Invitrogen (see 
Table 5.3 for siRNA sequences). Cells were plated in phenol red-free DMEM containing 
8% CS-FBS, 0.1 mM NEAA and 1 mM NaPyr in the presence of 40 nM siRNA or siRNA 
control using DharmaFECT-1 (Dharmacon, Lafayette, CO) as the transfection agent 
according to the manufacturer's recommendations. After 48 h of knockdown, cells were 
serum-starved in phenol red-free DMEM containing 0.1% CS-FBS, 0.1 mM NEAA and 1 
mM NaPyr for 24 h, then treated with the appropriate ligand and harvested for qPCR 
analysis as detailed above.  
Table 6-2: siRNA sequences. 
Company Reference Name Sequence 
Sigma SASI_Hs01_00168403 siFOXA1_1 CACACAAACCAAACCGUCA 
Sigma SASI_Hs01_00168404 siFOXA1_2 CGUACUACCAAGGUGUGUA 
Sigma SASI_Hs01_00168405 siFOXA1_3 CGCCUUACGGCUCUACGUU 
Invitrogen FOXA1HSS104878 siFOXA1_A GAACAGGCACUGCAAUACUCGCCUU 
Invitrogen FOXA1HSS104880 siFOXA1_B CAUGAAACCAGCGACUGGAACAGCU 
Invitrogen FOXA1HSS179280 siFOXA1_C CAGCAUAAGCUGGACUUCAAGGCAU 
Invitrogen FOXA2HSS142471 siFOXA2_A GCCGUCCGACUGGAGCAGCUACUAU 
Invitrogen FOXA2HSS142473 siFOXA2_B GCGGGCUCCAUGAACAUGUCGUCGU 
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Invitrogen FOXA2HSS179282 siFOXA2_C CACCCUGACUCGGGCAACAUGUUCG 
 
6.10 Western Blotting 
Cells were seeded in 6-well plates in phenol red-free DMEM containing 8% CS-
FBS, 0.1 mM NEAA and 1 mM NaPyr for 48 h and treated as indicated. Following 
treatment for the indicated time periods, cells were harvested in ice-cold PBS and lysed 
in RIPA Buffer [50 mM Tris-HCl pH 8.0, 200 mM NaCl, 1.5 mM MgCl2, 1% Triton X-100, 
1 mM EDTA, 10% glycerol, 50 mM NaF, 2 mM Na3VO4, and 1X protease inhibitor 
mixture (EMD Chemicals, Inc, San Diego, CA)] while rotating at 4°C for 30 min. 20 µg of 
whole-cell extract was resolved by SDS-PAGE, transferred to a PVDF membrane (Bio-
Rad) and probed with the appropriate antibodies.  
6.11  Chromatin Immunoprecipitation 
Cells were seeded in a 15cm dishes with appropriate media described above. 
Cells were grown to 90% confluence in phenol red-free media supplemented with 8% 
CS-FBS, 0.1 mM NEAA and 1 mM NaPyr for 48 h, after which the cells were treated as 
indicated. Following treatment with the appropriate ligand for the indicated time 
periods, cells were subjected to ChIP analysis. ChIP was performed as described 
elsewhere (DuSell et al., 2008) with modifications. Each plate of cells were cross-linked 
with 540ul of 37% formaldehyde (1% final concentration) for 10 minutes exactly and 
quenched with 2ml of 2.5M glycine (250mM final) for 5 minutes. Cells were then 
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harvested with cold PBS and snap frozen for storage at -80 degrees. qPCR analysis was 
performed in 384-well format with 4ul reactions and  data is normalized to the input for 
the immunoprecipitation. ChIP primer sequences are listed in Table 6-2. 
Table 6-3: ChIP primers used. 
Name Chr Start Stop 
TFF1-1 chr21 43786717 43786865 
S100A9-1 chr1 1.53E+08 1.53E+08 
S100A9-2 chr1 1.53E+08 1.53E+08 
S100A9-3 chr1 1.53E+08 1.53E+08 
CAV1-1 chr7 1.16E+08 1.16E+08 
CAV1-2 chr7 1.16E+08 1.16E+08 
CAV1-3 chr7 1.16E+08 1.16E+08 
WISP1-1 chr8 1.34E+08 1.34E+08 
WISP1-2 chr8 1.34E+08 1.34E+08 
WISP1-3 chr8 1.34E+08 1.34E+08 
AGR2-1 chr7 16825998 16826146 
AGR2-2 chr7 16844873 16845021 
AGR2-3 chr7 16851302 16851450 
XBP-1 chr22 29209832 29209980 
XBP-2 chr22 29215585 29215733 
XBP-3 chr22 29218960 29219108 
KRT13-1 chr17 39571364 39572125 
KRT13-2 chr17 39619973 39621791 
KRT13-3 chr17 39811719 39812650 
ASCL1-1 chr12 1.03E+08 1.03E+08 
SPDEF-1 chr6 34494339 34494461 
SPDEF-2 chr6 34524091 34524239 
SPDEF-3 chr6 34566308 34566935 
 
6.12  Preparation of Nuclear Extracts for Mass-Spec 
Antibody (60ug) was incubated with 90ul Protein A/G beads (Pierce #20421) in 
PBS overnight. The next morning beads were washed three times in .2M sodium borate, 
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pH 9.0. Complexed beads were conjugated with dimethylpimelimidate (DMP) with 
.0259g DMP and 5ml of .2M sodium borate to make a 20mM solution. Beads were 
incubated for 40min with end over end rocking at room temperature. After, beads were 
washed in .2M ethanolamine (pH 8.0) to quench residual DMP and then suspended in 
.2M ethanolamine for additional 1 hour incubation. Uncoupled antibody was then 
washed three times using .58% acetic acid with 150mM NaCl. Beads were stored in PBS 
with sodium azide at 4 degrees.  
Nuclear extracts of MCF7 and TamR cells was performed for Mass-Spec analysis. 
Briefly, fifteen 10cm plates were washed with PBS and harvested with .25% trypsin.  
Cells were scraped into a conical tube and spun for 5 min at 1500g in a pre-cooled 
centrifuge. Cell pellets were suspended in 5 times the cell pellet volume in hypotonic 
buffer for 5 min and thereafter checked every minute with trypan blue until greater than 
90% of cells stained positive.  NP40 was added to .1% (10ul/ml of 10% stock) and 
vortexed on mid setting for 10 seconds and immediately centrifuged at 3000g for 1 
minute. Resulting supernatant, predominately consisting of cytosolic extract was set 
aside and nuclear pellet was suspended in a half a cell pellet volume of low salt buffer 
[20mM HEPES pH 7.9, .02M KCl, .2mM EDTA, 25% Glycerol 1mM DTT, beta-
glycerophosphate, protease inhibitors, NaF, NaV, and NaB] being careful not to break 
nuclei. A half bed volume of high salt buffer [20mM HEPES pH 7.9, 1M KCl, .2mM 
EDTA, 25% Glycerol 1mM DTT, beta-glycerophosphate, protease inhibitors, NaF, NaV, 
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and NaB] was added gently and tube was rocked for 1 hour in cold room. Nuclear 
debris was pelleted at 14000g for 15 min and supernatant was dialyzed against dialysis 
buffer [20mM HEPES pH 7.9, 100mM KCl, .2mM EDTA, 20% Glycerol] to normalize 
salts for two changes at 1 hour each.  
Nuclear extracts were normalized at 10mg each and pre-cleared with A/G beads 
for 1 hour and then incubated overnight with the prepared conjugated beads. The next 
day beads were washed 5 times for minutes each with wash buffer [50mM HEPES pH 
7.9, .2% NP40, 150mM KCl, 1mM EGTA, 1mM DTT, beta-glycerophosphate, protease 
inhibitors, NaF, NaV, and NaB]. Final washes were performed using PBS three times 
and 50mM Ammonium Bicarbonate twice before submitting the Duke Proteomics core.  
6.13  DNase-Seq Library Generation 
DNase-Seq was performed as previously described(Song and Crawford, 2010; 
Song et al., 2011b). Briefly, cells were plated in CS-FBS in 15cm plates and treated 48 
hours later with either vehicle or 4-OHT for 24 hours before harvesting. Two 
independent biological replicates of each condition were prepared. Nuclei were 
extracted and digested with optimal concentrations of DNaseI enzyme. After 
confirmation of adequate digestion, DNaseI-digested ends were blunt ended, and a 
biotinylated linker was ligated to these ends. Fragments with linker attached were 
isolated, digested with MmeI, and captured using streptavidin-conjugated magnetic 
beads. A second linker was ligated to the MmeI-digested end, and then the fragments 
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were amplified and subsequently purified via gel electrophoresis. The libraries were 
sequenced using 50bp SR on Illumina HiSeq.  
6.14  DNase-Seq Analysis 
FASTQ files were aligned to the human female genome hg19 from UCSC using 
BWA (Li and Durbin 2009). Reads were filtered from the SAM file that do not align 
based on the 0X004 flag, align to multiple locations, align to more than two ambiguous 
location, and fall of chromosome boundaries using the chrom.sizes file from UCSC. 
Additional alignments were also filtered to remove problematic repetitive regions such 
as alpha satellites and sequence artifacts as defined by ENCODE. Biological replicates 
were compared for reproducibility and correlation.  Final base-pair resolution signal as a 
Wig file was generated using F-Seq at 300bp signal bandwidth (Boyle et al., 2008b) and 
converted to bigwig using the UCSC utility, WigtobigWig . Peaks were called by F-Seq 
and significance of the peaks were determined by fitting DNase-Seq signal data to a 
gamma distribution and then determining the signal value that corresponded to a p-
value < 0.05.  
Sequencing tags were quantified in each DNase peak for each condition using 
multicov from the bedtools suite(Quinlan and Hall, 2010).  Reads overlapping within 
500bp each direction from the TSS were also subset to discriminate against sites likely 
unrelated to TF binding using the Refseq annotated genes.  To identify regions of 
significant change across cell lines and treatments in DNase-Seq data, we used the 
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bioconductor package, edgeR (Robinson et al., 2010) and DESeq(Anders and Huber, 
2010). These packages use a negative binomial distribution to determine differential 
expression across treatment groups by fitting a generalized linear model. Both 
approaches yielded very similar results with the DNase data.  
6.15  Motif Analysis 
To determine motif enrichment adjacent to differential DHS sites we utilized 
used three distinct algorithms: MEME-ChIP(Machanick and Bailey, 2011), and CentDist 
(Zhang et al., 2011), and HOMER(Heinz et al., 2010).   De novo motif enrichment 
analysis was performed using MEME-ChIP which combines the MEME suite: MEME 
and DREME for motif discovery, Centrimo for central enrichment and TomTom for 
motif matching.  Notable parameters ( -meme-p 6 -meme-nmotifs 20 -meme-mod zoops 
-meme-minw 8 centrimo-local). A markov model was determined from the supplied 
differential sequences and additionally with a background defined from the union DHS 
sites. HOMER was run as both a de novo motif finding algorithm and separately against 
all known PWMs defined in the program. Background models were defined from 
differential DHS sites and again using union DHS sites to further discriminate the list. 
CentDist was run from the website with default parameters.  Reported motifs were 
considered concordant if found by at least two approaches and discordant if found only 
by one of the methods. 
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